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The lymphatic system is composed of vessels and nodes and exists in almost all of 
the soft tissue of your body. It plays a large role in maintaining fluid homeostasis, immune 
cell trafficking, and lipid transport. Interstitial fluid that enters the lymphatic system 
through initial lymphatics is deemed “lymph” and is transported from the anatomical 
region where it is collected to the blood circulation. Unlike the venous system, lymphatic 
vessels must actively pump to drive lymph flow. Lymphatic dysfunction often leads to the 
development of swelling known as lymphedema. This buildup of fluid alters loading 
conditions of the local lymphatic network and lymphedema eventually leads to remodeling 
of the interstitium and lymphatic vessel walls. The extent to which remodeling of these 
extracellular matrices (ECM) is the cause and/or symptom of lymphatic dysfunction is not 
clearly understood.  
We present multiple studies utilizing engineering tools to better understand how the 
biomechanical properties and loading of the extracellular matrix regulate lymphatic 
function. We establish a healthy and remodelled lymphatic muscle cell (LMC) line and 
explore how LMC phenotype impact their response to 2D culture conditions.  We 
demonstrate regulation of LMC molecular pathway expression via physiologically relevant 
levels of cyclic stretch. Modular poly(ethylene glycol) (PEG) based hydrogels are used to 
explore the sensitivity of sprouting lymphangiogenesis to properties of the extracellular 
matrix. PEG gels can be formulated to produce a robust sprouting network that is sensitive 
to a variety of molecular regulators. Finally, we present results demonstrating that the PEG 
hydrogels can be used to successfully transplant lymphatic tissue after damage to local 
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lymphatic collecting vessel or lymph nodes. Tissue transplanted with this method becomes 






CHAPTER 1. INTRODUCTION 
1.1 General Background 
1.1.1 General Anatomy and Structure of the Lymphatic System  
Lymphatics are composed of a system of vessels and nodes responsible for returning 
roughly 8 liters/day of fluid from the interstitial tissue space back into blood circulation, 
Figure 1. The lymphatics play a critical role in maintaining fluid homeostasis, trafficking 
immune cells, and transporting lipids1. The initial lymphatics, sometimes referred to as 
lymphatic capillaries, are blind ended vessels composed of lymphatic endothelial cells 
(LECs). LECs of the initial lymphatics are connected via “button-like” junctions, 
composed of a unique configuration of VE-Cadherin and CD31, and form flap like 
structures providing structural integrity along the side of the flap and at the points of entry 
at the tips2. This allows for fluid, large proteins, and cells to enter the initial lymphatics. 
Once in lymphatic vasculature, this unique mixture of fluid, proteins, and cells is deemed 
lymph. Entry of fluid and other macromolecules is further assisted by anchoring filament 
that connect the initial lymphatics to the surrounding interstitial tissue and prevents these 
vessels from collapsing when the interstitial fluid pressure increases3,4. Furthermore, the 
junctions are aligned in such a way that prevents the escape of lymph from the initial 
lymphatics even when lymphatic capillary pressure exceeds interstitial fluid pressure. This 
functionality gives the initial lymphatics a valve-like quality, commonly referred to as 
“primary lymphatic valves” 1,5–8.  These unique features of initial lymphatics are outlined 
in Figure 1. 
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As initial lymphatics begin to connect downstream they form larger lymphatic 
vessels known as pre-collecting vessels. These pre-collecting vessels are characterized by 
the formation of a basement membrane surrounding the endothelial cells and sporadic 
coverage by specialized smooth muscle cells referred to as lymphatic muscle cells (LMCs). 
Despite the basement membrane, pre-collectors continue to have anchoring filaments, 
presumably to assist in lymph transport and structural support9.  
Pre-collecting vessels transition in mature lymphatic collecting vessels with 
continuous LMC coverage and the presence of unidirectional valves. The mature basement 
membrane between the LECs and LMCs is primarily composed of collagen and elastin 
fibers and provides full structural support to the vessel. Collagen and elastin also provide 
support to the bileaflet, unidirectional, valves that are spaced every 1-3 millimeters in 
humans 10,1112. In addition to limiting the backflow of lymph within the lymphatic system, 
these valves allow us to separate the collecting vessel into discrete functional units known 
as lymphangions, the region of vessel between two valves, Figure 2. The valves are slightly 
biased to remain open, explaining why there is a small amount of retrograde flow observed 
in the upstream lymphangion before valve closure13 14. 
There is no central pump to drive lymph flow within the lymphatic system and there 
is no passive pressure gradient that would allow for continuous flow downstream. 
Therefore, lymph transport is dependent on the intrinsic contractility of the highly 
specialized lymphatic muscle cells.  LMCs are capable of coordinated, phasic, contractions 
to propel lymph from one lymphangion to a downstream lymphangion15. The unique 
physiology of the lymphatic muscle cells will be explored in more detail in the following 
sub-section. In addition to LMC contractility, extrinsic factors, such as skeletal muscle 
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contractions, arterial pulsations, passive movements, and respiration contribute to lymph 
flow by expanding or constricting nearby lymphangions7,16. Failure of lymphatics to 
successfully transport lymph forms the basis of most lymphatic diseases, such as 
lymphedema, resulting in chronic swelling of the soft tissues.  
Afferent collecting vessels eventually lead to lymph nodes where some lymph is 
“processed” by resident immune cells and some lymph enters the blood circulation via high 
endothelial venules (HEV) within the node17. The majority of lymph continues out of the 
lymph node through efferent collecting vessels and eventually into large lymphatic ducts.  
The two major lymphatic ducts are directly connected to the subclavian veins, separated 
by a unidirectional lymphovenous valve, that allows lymph to be deposited into the venous 
circulation but prevents blood flow back into the lymphatics. This network of fluid 
drainage across the body, the unique primary lymphatic valves that allow for entry of cells 
and macromolecules, and the relatively slow flow rate of lymph compared to blood flow 
assist the lymphatics in their additional roles of transporting cells, proteins, lipids, and other 




Figure 1: Overview of lymphatic structure and anatomy. (A) Structure of the 
lymphatic network and how initial lymphatics collect tissue fluid and connect 
downstream to the collecting lymphatic vessel. (B) The initial lymphatic vessels 
exhibit a discontinuous basement membrane and loose endothelial cell junctions, in 
contrast to blood capillaries that have a continuous basement membrane. This 
specialized structure of the initial lymphatics allows the paracellular transport of cells 
and proteins into the initial lymphatic lumen, but transport also happens through 
transcellular pathways. Anchoring filaments, which are responsible for pulling the 
initial lymphatic vessel open during the filling up stage are also shown. Modified from 
the publications of Yu et al, 200918 (top) and Stacker et al, 201419 (bottom). 
1.1.2 Lymphatic Muscle Physiology and Remodelling 
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As stated earlier, lymphatic muscle cells (LMCs) play a primary role in generating 
lymph flow. They are arranged circumferentially around the lymphatic collecting vessels 
with brief interruptions around the valve regions20. These valves also break the collecting 
vessel into discrete contractile units referred to as lymphangions (Figure 2). Contractions 
are coordinated with depolarization waves traveling across adjacent cells to coordinate 
contractile waves. Influx of calcium through T-type and L-type calcium channels helps to 
regulate the frequency and amplitude of these contractions21–23. LMCs contain the majority 
of contraction proteins found in vascular smooth muscle cells (VSMCs), including vascular 
α-smooth muscle actin, smooth muscle myosin heavy chains, myosin light chains, and 
tropomyosin15,24–26. In addition, LMCs contain contractile proteins typically reserved to 
striated muscle cell. Freshly isolated collecting vessels have stained positive for, skeletal 
actin, and cardiac actin. Furthermore, it has been demonstrated that some collecting 
vessels, from regions such as the mesentery, express cardiac troponin and cardiac/skeletal 
slow-twitch β-myosin heavy chains, but expression levels of these highly specialized 
proteins seem to vary depending on the anatomical region of the collecting vessel. While 
the exact functional implications of these proteins within LMCs are still being explored, 
the presence of these proteins help to explain their unique contractile capacity. 27. For 
example, the peak maximum shortening velocity (Vmax) of mesenteric lymphatic vessels 
has been measured to be 0.48 ±0.04 lengths/s, which is 2.3 times higher than mesenteric 
arteries and 11.4 times faster than mesenteric veins28. A chain of lymphatic vessels is able 
to overcome a relatively large pressure gradient, with measurement in vivo reporting 
pumping pressures in excess of 30 mmHg  in human legs 29, 40 mm Hg in human arms 30, 




Figure 2: The mature lymphatic collecting vessel. (A) Cross-sectional view of the 
collecting vessel showing luminal lymphatic endothelial cells (off-white) surrounded 
by a single layer of lymphatic muscle cells (red). (B) The lymphatic endothelial cells 
(LECS) are supported by a layer of basement membrane composed primarily of 
extracellular fibrils of collagen and elastin (seen in orange and blue). These fibers also 
provide structural support to the bileaflet valves. The entire collecting vessel is 
surrounded by a layer of lymphatic muscle cells which contracts to propel lymph flow 
downstream. Panel A adapted from Tammela et al, 2010. 
A major challenge to researching LMCs  is the loss of many of their unique proteins  
when cultured in-vitro (Figure 3)15. After seeding onto plastic, LMCs lose expression for 
much of the skeletal/cardiac proteins. LMCs also alter their expression of many markers of 
mature smooth muscle cells, such as an overexpression of vascular smooth muscle actin 
and a reduction in smooth muscle myosin heavy chain II (SM2), Figure 3. In VSMCs a 
similar change in protein expression  has been shown to be indicative of a phenotypic 
change32–34. VSMC phenotype is considered plastic, with cells changing from a fully 
differentiated, “contractile” phenotype when in a healthy vessel, to a “synthetic” 
phenotype” under pathological or unnatural conditions, such as in response to vessel 
damage, hypertension, or during in-vitro culture. This synthetic state is associated with 
elevated proliferation, migration, and increased synthesis of extracellular matrix. To what 
extent LMCs exhibit a similar synthetic phenotype and the exact implications of the protein 




Figure 3: Altering LMC protein expression between mesenteric lymphatic muscle 
(MLM), thoracic duct lymphatic muscle (TLM), in-vitro cultured lymphatic muscle 
(LM. Cells), and arterioles (vessels). (A) PCR analysis of common actin isoforms of 
freshly isolated mesenteric lymphatic muscle. (B) PCR analysis of actin expression in 
LMCs isolated from mesenteric lymphatic vessels after 7-10 days of culture in-vitro. 
Gene expression for cardiac actin has been significantly reduced. (C) Western Blot 
showing that smooth muscle myosin heavy chain 2 (SM2) expression is absent in the 
in-vitro LMC cultures. (D) Western Blot reveals that only mesenteric lymphatic 
muscle (MLM) expresses the β isoform of myosin heavy chain. All panels modified 
from Muthuchamy et al, 200335. 
1.1.3 Lymphatic Dysfunction and Lymphedema 
Lymphedema is defined as swelling, generally occurring in the extremities, due to 
lymphatic impairment or blockage. Swelling typically manifests as “pitting edema” and 
can be accompanied with restricted range of mobility and fibrosis of the skin36–38. Primary 
lymphedema due to inherited, genetic, factors is rare. Typically, primary lymphedema will 
manifest at infancy, but there are cases of mid or late onset primary lymphedema that are 
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linked to genetic causes.  Secondary lymphedema is much more common and occurs when 
lymphatic function is impaired due to another known disease or injury. Globally, the 
biggest cause of lymphedema is due to lymphatic filariasis which is caused by a parasitic 
worm that resides in lymphatics and is transmitted via mosquito bites. Filariasis deposited 
under the skin during a bite will migrate to the lymphatic system and disrupts healthy 
lymphatic function. In most developed countries, lymphedema is primarily the result of 
cancer related surgery and treatments and is particularly documented to occur after breast 
cancer. Due to a mixture of the surgery to remove the primary tumour, lymph node removal 
to limit cancer metastasis, radiation, and/or chemotherapy, an estimated of 10-20% of 
breast cancer patient survivors will develop lymphedema at some point in their life39. While 
the swelling and other symptoms of lymphedema are manageable if diagnosed early, there 
is no cure and most patients must maintain some level of therapy to avoid reoccurrence. 
Patients who are diagnosed late are burdened with a lifetime of disease management which 
can often result in pain, severe disfigurement, compromised immune function, and an 
increased rate of infection. 
While the exact cause and pathogenesis of breast cancer related lymphedema 
(BCRL) is unknown, our understanding of risk factors and symptoms is growing. 
Historically, there have been several perceived  risk factors including the severity of 
surgeries and number of lymph nodes removed, total dose of radiation , patient age, BMI, 
and others but there is limited clinical data to quantify the relative importance of each40. 
Recent work has shown that patients with elevated lymphatic pumping prior to breast 
cancer related treatments are much more likely to develop lymphedema later on41,42. These 
studies indicate that patients that go on to develop lymphedema have a predisposition to its 
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development regardless of surgery or treatments. Lymphatic workload and output increases 
further following lymph node dissection and cancer treatments and eventually tip into 
chronic failure. Furthermore. once lymphedema has been acquired it has been shown that 
pressures are elevated in lymphatic capillaries compared to healthy individuals43. Taken 
together, these studies would imply a pathology analogous to high preload and high 
afterload cardiac failure in systemic hypertension, but definitive studies to support this 
failure model have yet to be thoroughly conducted.  
These results indicate that the workload on the collecting vessel is critical to the 
development and progression of lymphedema and therefore recent studies have begun to 
look more closely at the function and structure of lymphatic collecting vessels during 
lymphedema progression. It has been found that vessels undergo hyperplasia and a 
narrowing of the lumen during late stages of lymphedema44. Collecting vessels see an 
increase in SMA positive cells, collagen in and around the vessel walls, and a reduction in 
SM2 positive cells45 (Figure 4). The lymphatic specific mechanisms of how these changes 
occur in LMCs is unclear, but the morphological changes noted so far are reminiscent of 
the synthetic phenotype in vascular smooth muscle cells. It has been well documented that 
VSMCs in hypertensive or atherosclerotic vessels become more proliferative, mobile, and 
excrete additional ECM to thicken vessel walls46, but much more research remains to be 
done to explore the extent of these similarities in lymphatic vasculature. While we have 
begun to understand that lymphatic collecting vessels near an injury never return to 
pre-injury levels of pumping and lymph transport47, long term remodeling of 





Figure 4: Progression of Lymphatic Collecting Vessel Phenotype During Leg 
Lymphedema Progression. As lymphedema worsens, shown as a progression from 
grade 1 to grade 3, the collecting vessel walls become thicker and the lumen becomes 
more stenotic. αSmooth muscle actin (SMαA) positive cells proliferate and expand, 
lymphatic muscle cells eventually lose their expression of smooth muscle myosin 
heavy chain 2 (SM2), and the collagen composition of the vessel wall increases. 
Modified from Ogata 2015 45 
In animal models, it has been found that lymphedema is dependent on macrophage 
and CD4+ T-cell presence. These immune cell populations are associated with worsening 
lymphedema through a variety of mechanisms including fibrosis, increased ECM synthesis 
and tissue remodeling and inflammation driven lymphangiogenesis48,49. Inhibition of 
fibrosis through manipulation of immune cell recruitment has been shown to reduce 
swelling and improve lymphatic function following surgical insult50. Inflammation driven 
lymphangiogenesis appears to have a mixed role in lymphedema pathology. In some 
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studies, VEGF-C driven lymphangiogenesis has been shown to reduce swelling in animal 
models of lymphedema, while other studies have shown that it may worsen outcomes51–54.  
As the context and extent of lymphangiogenesis can sometimes propagate or alleviate 
dysfunctional states it is unclear how to best regulate lymphangiogenesis as a therapy55.  
These discrepancies may in part be due to variation in how VEGF-C levels are elevated 
(exogenous application vs cellular overexpression) and variation in animal models of 
lymphedema. Recent work has shown that the benefits of lymphangiogenesis during 
lymphedema progression are also dependent on when the intervention begins following 
surgical insult56. Due to their critical role in regulating lymphedema outcomes, we need 
a better understanding of lymphangiogenesis following surgical insult and the 
regulatory role of the ECM on lymphatic function.   
1.1.4 Lymphangiogenesis 
Lymphangiogenesis is the process of proliferation and migration of lymphatic 
endothelial cells to form new functional initial lymphatic vessels and has been the focus of 
lymphatics research for decades57,55,58,59. Lymphatic endothelial cells express vascular 
endothelial growth factor receptors (VEGFR), which trigger growth and proliferation of 
the cell once bound to their ligand. Unlike vascular endothelial cells, LECs primarily 
express the VEGFR-3 subtype which binds with the highest affinity to vascular endothelial 
growth factor C (VEGF-C). Since this discovery, VEGFC has been used successfully in 
numerous studies to drive lymphatic growth in-vitro and in-vivo60. More recently it has 
been shown the VEGF-C driven lymphangiogenesis can produce leaky initial lymphatics 
that can possibly propagate disease states, adding a layer of complexity to its application 
as a therapy to lymphatic dysfunction51,61,62. Recent research has shown that there is a 
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heterogeneity to VEGFR-3 expression in developing or immature initial lymphatics. 
Lymphatic endothelial cells along the leading edge of sprouts, commonly referred to as the 
tip cells, have higher levels or VEGFR-3 and their behavior is reliant on molecular 
regulators such as neuropilin-263–65.  
1.1.5 The Extracellular Matrix (ECM) of the Basement Membrane and Interstitial Tissue 
The collecting vessel wall is supported through a basement membrane that is 
composed of a variety of extracellular matrix proteins. As initial lymphatics transition into 
precollectors a patchy basement membrane of both laminin and type IV collagen has been 
observed66. The collecting vessel wall has a basement membrane that is composed of an 
inner layer of elastin and an outer layer of collagen fibers67,68. Cells of the vessel wall 
interact with this wall matrix with a variety of surface receptors known as integrins, which 
bind to specific regions along the fiber. The expression and binding of specific integrins to 
their ligands along the ECM fiber has been shown to guide lymphatic function69–71. During 
events that trigger lymphangiogenesis, such as injury and inflammation, the type and 
number of activated integrins change significantly which seems to promote migration and 
proliferation. In LECs these activated integrins include α9β1 α4β1 α2β1 α1β172. There is 
no available research looking at the change in LMC integrin expression during 
lymphangiogenesis or following injury, but literature from VSMCs would suggest that 
LMCs may also undergo altered integrin expression. For example, VSMCs begin to 
upregulate the α5β1 integrin isoform in response to arterial injury73,74. Similarly blocking 
α5β1 integrin binding blocked inflammation driven lymphangiogenesis in the airway, 
although in this study α5β1 integrin expression was associated exclusively with sprouting 
lymphatic endothelial cells, not muscle cells75. Generally, the collecting vessel remodelling 
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that occurs during lymphatic disease states, such as elevated, dense, type I collagen 
synthesis, would presumably impact the number and types of adhesive peptides available 
to the cells of the vessel wall.  
Matrix stiffness has a large impact on cell phenotype. It has been shown that matrix 
stiffness can guide stem cell differentiation, cell migration, protein synthesis and more76–
78. For example, it has been shown that in development the migration of LEC progenitors 
from the cardinal vein to the softer surrounding matrix triggers GATA2 transcriptional 
factors needed to form initial lymphatic vessels79. Changes in arterial stiffness with age or 
disease have been linked to propagating disease states and triggering vascular smooth 
muscle cells to proliferate and remodel the vessel walls. The ideal stiffness for each cell 
type is different but it is typically bimodal, with matrices that are too soft preventing 
adequate traction force generation and matrices that are too stiff often preventing migration 
or inducing a pathological phenotype80–82.  Biologically, matrix stiffness is intricately tied 
to the density of ECM components. A stiff matrix is typically less porous and more heavily 
crosslinked, requiring higher levels of specific enzyme to degrade the matrix before cell 
migration is possible. When examining the mechanical properties of the collecting vessel 
it is important to consider its loading condition. At low transmural pressures, the ECM 
fibers of the basement membrane will not be engaged and therefore the perceived wall 
stiffness to the cells will be low. At high transmural pressures the fibers will fully engage 
increasing the relative stiffness and the necessary force for the muscle cells to contract the 
vessel68,83. Therefore, even without matrix remodeling, elevated loading can alter the 
stiffness based signaling cues to the embedded cells.  
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The interstitium is composed primarily of collagens I, III, and V, elastin, and 
glycosaminoglycans. These components are both mechanically entangled and cross-linked 
forming a gel-like matrix to provide structural support for tissues and migrating cells. The 
exact components of the interstitial tissue, and therefore the biomechanical properties, vary 
greatly across different regions of the body and as such lymphatics have local variability 
in density, size, and contractility84–87. The density of the ECM is dynamic with fluid content 
playing a large role in the density of fibers, thereby altering porosity, volume, and fiber 
tension. Two prominent cell populations that reside in the ECM are fibroblasts and tissue 
resident immune cells (such as macrophages and dendritic cells). Fibroblasts are primarily 
responsible for both synthesizing ECM components and can release a variety of enzymes 
to degrade matrix components allowing for migration and remodelling88,89. Among these 
enzymes are the family of matrix metalloproteinase.  Both endothelial cells and smooth 
muscle are capable of excreting many MMPs as well, which allow for their migration and 
remodelling of vessel basement membranes. 
1.2 Specific Aims 
The central goal of this work is to better understand how the loading conditions and 
properties of the extracellular matrix (ECM), regulate the phenotype and regenerative 
capacity of the lymphatic cells that compose the collecting vessels’ walls. This goal is 
accomplished through the following three aims. 
1.2.1 Specific Aim 1: Determine the role of in-vitro mechanical stretch in the remodelling 
response of lymphatic muscle cells. 
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While the phenotypic switch of vascular smooth muscle cells (VSMCs) during disease 
states or 2D culture has been well characterized90–92, the extent to which lymphatic muscle 
cells are capable of this phenotypic plasticity is unclear. As outlined, recent studies 
characterizing isolated lymphatic collecting vessels support the hypothesis that LMCs 
behave similarly to synthetic VSMCs during lymphedema progression. The synthetic 
phenotype is characterized by a down-regulation of contractile markers, such as myosin, 
an up regulation of actins, and elevated synthesis of ECM components34,91. We isolate 
LMCs from a sheep model of lymphatic dysfunction and compare the behaviour of LMCs 
isolated from the remodelled lymphatic vessel in the surgically insulted limb to an internal 
control LMC line established from the contralateral limb. We demonstrate a chronic 
increase in metabolic activity and oxidative stress in the LMCs isolated from the 
remodelled vessel.  
We hypothesize that this remodelled, or “wounded” phenotype impacts the sensitivity of 
LMCs to loading conditions. We modify and characterize a stretch device platform to apply 
physiologically relevant levels of cyclic mechanical strain to 2D cultures of LMCs. Stretch 
profiles are based on contraction metrics of in-vivo lymphatic collecting vessels during a 
surgically induced lymphedema model in sheep, where the LMCs were derived from.  
1.2.2 Specific Aim 2: Characterize sprouting lymphangiogenesis sensitivity to 
extracellular matrix properties using a modular poly(ethylene glycol) (PEG) 
hydrogel.  
It has been well demonstrated that the components and density of the ECM alone have a 
significant impact on the phenotype of a cell76–78, leading to changes in the form and 
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function of a cell.  Fibrosis and inflammation alter the properties of the interstitial ECM 
following surgically induced lymphedema49,93, but the sensitivity of lymphatic repair 
mechanisms such as sprouting lymphangiogenesis, to ECM properties is poorly 
understood.   
In this aim we begin to answer this question by determining the baseline sensitivity of 
sprouting lymphangiogenesis to various ECM properties. Through implementation of a 
modular, poly(ethylene glycol) hydrogel, we systematically determine which ECM 
properties significantly impact sprouting from segments of lymphatic collecting vessels. 
We hypothesize that a degradable hydrogel that facilitates high affinity adhesion of 
lymphatic cells, will optimize sprouting as measured by sprout length and abundance. 
Stiffness, degradability, and adhesive ligands will be independently configured to optimize 
sprouting and the best performing gel condition will then be used to determine sprouting 
sensitivity to other drugs and molecular regulators. 
1.2.3 Specific Aim 3: Utilize animal lymphatic damage models to study PEG hydrogel 
facilitated lymphatic tissue transplantation and influence of PEG hydrogels on 
lymphatic function and regeneration following injury. 
Transfer of healthy lymphatic tissue or cells to a region of lymphedema or surgically 
induced lymphatic dysfunction has shown promising preliminary results in mitigating 
lymphedema symptoms in both animal models and human patients94,95. This field is still 
growing, and the exact mechanisms and pathways that facilitate successful transfer are still 
being determined. Given the robust sprouting produced in the degradable 10% PEG – 2mM 
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RGD gels characterized in aim 2, we wish to determine if these PEG gels could be used to 
enhance lymphatic regeneration and minimize lymphatic dysfunction in-vivo.   
We hypothesize that the sprout promoting characteristic of the PEG hydrogel will enhance 
repair of lymphatic tissue into a region where lymphatics are damaged and surgically 
resected. In our first animal model we aim to determine if lymphatic tissue transfer is 
feasible when embedded within our PEG hydrogel formulation. Given the success of this 
first model, we then use a second animal model to examine the impact of PEG hydrogel 
facilitated lymph node transfer compared to the innate repair process without intervention 
and to alternative biomaterial approaches. In the process we also assess the response of 





CHAPTER 2. DETERMINE THE ROLE OF IN-VITRO 
MECHANICAL STRETCH IN THE REMODELLING RESPONSE 
OF LYMPHATIC MUSCLE CELLS.  
2.1 Overview 
Objective: Using primary lymphatic muscle cells (LMCs) in vitro we sought to 
characterize the impact of LMC remodeling on their functional and molecular response to 
mechanical loading and culture conditions. 
 Methods: Primary “wounded leg” LMCs were derived from the hindlimb of three sheep 
who underwent lymphatic injury six weeks prior, while “control leg” LMCs were derived 
from the contralateral, unwounded, limb. Functions of the LMCs were characterized in 
response to media of variable levels of serum (10% vs 0.2%) and glucose (4.5g/L vs 1g/L). 
Additionally, functional and proteomic data were evaluated in LMCs exposed to cyclic 
stretch (0.1Hz, 7.5% elongation) for 1 week. 
Results: LMCs were sensitive to changes in serum levels, significantly reducing overall 
activity and collagen synthesis under low serum conditions. LMCs from the remodeled 
vessel had higher baseline levels of metabolic activity but not collagen synthesis. Cyclic 
loading induced cellular alignment perpendicular to the axis of stretch and alterations in 
signaling pathways associated with metabolism. Remodeled LMCs had consistently higher 
levels of metabolic activity and were more resistant to strain induced apoptosis. 
Conclusions: LMCs exist on a functional spectrum, becoming more active in response to 
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stretching and maintaining phenotypic remodeling in response to local lymphatic/tissue 
damage.   
2.2 Motivation and Background 
As stated previously, the primary driver for lymph transport is the intrinsic 
contractility of lymphatic muscle cells (LMCs). Despite their unique phenotype and 
importance in generating fluid transport, the role of lymphatic muscle in mediating or 
propagating pathologies such as lymphedema has been largely understudied. Functionally, 
it has been demonstrated that lymphatic collecting vessels become more permeable in 
inflammatory environments and significantly remodel96–98. Vessels removed from 
lymphedema patients undergoing lymphaticovenous anastomosis displayed a thicker 
media and intima when the stage of lymphedema was advanced, decreased ratio of myosin-
heavy-chain-2 to alpha-smooth muscle actin and increased collagen49,99. In the 
lymphedemic environment, the phenotype of the lymphatic collecting vessel is sensitive to 
various macrophages and inflammatory signaling that regulate tissue remodeling through 
fibrosis49,100.  Understanding the remodeling response of lymphatic muscle to injury and 
pathology, and the role that the mechanical tissue microenvironment plays in this process, 
may provide useful insight into the chronic nature of lymphedema. 
LMC’s response to local injury and disease is likely to be similar in many ways to 
vascular smooth muscle cells (VSMCs). The behavior of VSMCs have been characterized 
in much greater detail both in-vivo and in-vitro. Depending on the combination of chemical 
and mechanical cues, VSMC phenotype is typically described as “contractile” or 
“synthetic” 91,101,110–112,102–109. In the contractile phenotype, VSMCs tend to be quiescent; 
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with little to no migration or proliferation. A contractile VSMC’s primary function is to 
modulate the diameter of a blood vessel through constricting or relaxing in response to 
biomechanical cues such as endocrine signaling or pressure changes. Commonly in 
response to pathological stimuli, such as disease or vessel damage, VSMCs convert to a 
synthetic phenotype. In this phenotype, VSMCs are highly proliferative and migratory. In 
addition, they begin to excrete a variety of extracellular matrix (ECM) proteins, such as 
collagen. In combination, proliferation and ECM synthesis from high levels of synthetic 
VSMCs thicken and alter the walls of blood vasculature in disease states. Studies have 
demonstrated that the contractile and synthetic phenotypes do not exist exclusively, and in-
vitro assays using a variety of different chemical and mechanical cues can induce a VSMC 
phenotype that exhibit features of both phenotypes90. While much of the LMC pathological 
response could be characterized as existing on this contractile to synthetic spectrum as well, 
it is unclear how the distinct functions of LMCs may lead to differences in their 
pathological responses. 
At this time, LMC phenotype and function have mostly been explored while part of 
an intact vessel23,35,113–115, limiting the opportunity for systematic, high throughput, 
analysis of multiple factors and stimuli. Therefore, with this study we aim to assess the 
impact of common biochemical and mechanical culture conditions on the phenotype of 
LMCs in-vitro. Primarily we explore the chronic phenotypic changes that occur in 
lymphatic smooth muscle derived from a limb where surrounding lymphatic vessels were 
surgically removed and compare those responses to LMCs isolated from the contralateral 
control. We determine the sensitivity of LMC phenotype to common changes in culture 
media thought to regulate phenotype. Specifically, we examine how changes in medium 
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serum and glucose levels, in addition to cyclic loading, alter LMC morphology, metabolic 
activity, and synthesis of collagen. Furthermore, we examine how cyclic stretching of 
LMCs influence orientation and the expression of various molecular pathways.  We further 
demonstrate that LMCs derived from an inflammatory in-vivo environment, following 
local tissue damage, chronically alter the state of lymphatic muscle and their response to 
bio-mechanical cues.  
2.3 Materials and Methods 
2.3.1 Surgical Overview and Lymphatic Tissue Collection 
A total of five, 3 to 5-year-old randomly bred female Suffolk sheep were used in 
this study; Before the study, 3 of the sheep underwent Gadolinium-Enhanced MR imaging 
(GE MRI) to structurally map the lymphatic anatomy of the hind limbs. One day after the 
MRI the sheep underwent a collecting lymphatic ligation surgery on one of the hind limbs, 
with the contralateral limb remaining intact to act as an internal control. In brief, a 4 cm 
incision was made on the lateral aspect of the hind limb proximal to the tarsus, exposing 2 
collecting lymphatic vessels running in parallel to the saphenous vein, one cranial and one 
caudal with respect to the animal. A 2 cm portion of the caudal vessel along with the vein 
was ligated with sutures and resected. The sheep were recovered from anesthesia following 
the final NIR imaging session and surgery. Near-infrared (NIR) functional lymphatic 
imaging was conducted prior to the surgery, as well as 7, 14, 28, and 42 days after the 
procedure. One day before the final NIR imaging session, the 3 sheep that underwent the 
MR lymphatic imaging underwent a second MR imaging session. On day 42, following 
the NIR imaging procedure, the sheep were not recovered and were euthanized via 
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pentobarbital overdose for tissue collection. The cranial collecting lymphatic vessel that 
was left intact on the wounded leg, and the corresponding cranial vessel on the contralateral 
control limb, were isolated and excised for cell collection. 
2.3.2 Cell Culture 
Primary lymphatic muscle cell (LMC) lines were formed from cranial collecting 
lymphatic vessels isolated from wounded and control hind limbs. Once isolated, the 
collecting vessels were cleaned from all adipocytes and rinsed in a physiological saline 
before being transferred to a tissue culture dish where they were attached by gently pressing 
the ends to the surface with forceps. Vessels were cultured in Dulbecco’s Modified Eagle’s 
Medium (ThermoFisher Scientific, Waltham, MA), 4,500mg/L of glucose, with 10% Fetal 
Bovine Serum (FBS), along with Antibiotic-Antmycotic (ThermoFisher Scientific). Media 
was exchanged every 2-3 days. Muscle cells began to migrate and proliferate from the 
vessel around day 3. The vessel was gently discarded, leaving only the newly migrated 
cells. Cells were split once confluent using Trypsin, 0.25% EDTA, and frozen in liquid 
nitrogen at passage 3. Experiments were conducted on LMCs between passage 5-6. All 
following experiments were done with LMCs derived from 3 separate sheep, all who 
underwent the same lymphatic injury surgery, creating 6 cells lines. For statistical analysis 
experimental conditions were grouped into cells isolated from the wounded leg (3 sheep) 
and cells isolated from the control leg (3 sheep).  
Lymphatic endothelial cells were isolated by first inverting a segment of the isolated 
collecting lymphatic vessel so that the luminal endothelial cells would be on the exterior. 
One end of the collecting vessel was tied to the end of a long glass micropipette and 
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inverted using suction and removed from the micropipette. The inverted lymphatic vessel 
was then gently pressed to a petri dish and cultured in Endothelial Basal Medium (Lonza, 
Basel, CH), supplemented with 20% FBS, 1% penicillin-streptomycin-amphotericin B 
(Gibco), 1% Glutamax (Gibco), 0.1% DBcAMP (Sigma), and 0.1% hydrocortisone acetate 
(Sigma), until the LECs began to migrate away from the vessel, usually around day 2-3. 
The vessel was then discarded and the cells were cultured until confluent. Cells were split 
using Trypsin, 0.25% EDTA, and frozen in liquid nitrogen at passage 3. 
Immunohistochemistry was conducted on LECs at passage 5.  
2.3.3 Marker Assessment 
Purity of the cell culture lines was established through expression of key protein 
markers including endothelial nitric oxide synthase (Abcam, Cambridge, UK), alpha-
Smooth Muscle Actin (Sigma, St Louis, MO), Collagen Type 1 (Sigma), and Tropomyosin 
(BD Biosciences, San Jose, CA). Samples were permeabilized with methanol (-20C) for 2 
minutes then rinsed three times with phosphate buffered saline (PBS). Blocking of samples 
was done in a PBS solution containing 2% bovine serum albumin, BSA and 10% goat 
serum for 1 hour at room temperature. Following this, a primary antibody, suspended in 
the 2% BSA solution (1:100), was applied to the samples for one hour on a plate rocker. 
The samples were rinsed in PBS before application of a fluorescent secondary antibody 
solution in 2% BSA (1:200) for 1 hour at room temperature on a shaker. Samples were 
rinsed two times in PBS before imaging. 
2.3.4 Media Assay 
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To explore the role of serum levels and glucose levels in the phenotype of LMCs, cells 
were seeded into a cell culture treated 48-well plate at a density of 14800 cells/cm2 in our 
standard DMEM formulation. This DMEM contained 4,500mg/L glucose and was 
supplemented with 10% FBS. Cells were allowed to settle and attach overnight before 
being serum starved for 24 hours in standard DMEM supplemented with 0.2% serum to 
arrest cell cycle progression. After serum starvation, cells were grown in one of three types 
of media for two days; the standard DMEM formulation (4,500 mg/L of glucose and 10% 
FBS), a low serum DMEM formulation (LS-DMEM) with only 0.2% FBS, or a low glucose 
DMEM formulation (LG-DMEM) containing only 1000mg/L of glucose.  
2.3.5 Cellular Metabolic Activity  
A reduction-oxidation indicator known as alamarBlue® (ThermoFisher Scientific) both 
fluoresces and undergoes a colorimetric change in response to cellular metabolic activity. 
Specifically, resazurin, a blue cell permeable compound with low fluorescence is reduced 
to resorufin, a red shifted and highly fluorescent compound. This reduction of resazurin to 
resorufin is a byproduct of normally occurring reduction reactions in metabolically active 
cells. Each well from the stretch experiment was incubated in media containing 10% 
alamarBlue® reagent for 4 hours. After the 4 hours, 100μL of the media from each well 
was transferred to a 96-well plate. The fluorescent intensity of each sample-including well 
was measured using a plate reader (Synergy H4) after excitation with a 562nm wavelength 
laser. 
2.3.6 Collagen Expression Assay 
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A Sirius red/fast green assay (Chondrex, Redmond, WA) was used to determine the amount 
of collagen produced by cultured LMCs. In short LMCs were cultured on a tissue culture 
treated 48-well plate. Cells were cultured at a density of 15,000 cells/cm2. Cells attached 
overnight and then were serum starved for 24 hours. Following the serum starvation, media 
of a specific formulation was applied, and the cells were cultured for two days before being 
fixed in 4% PFA. 75μL of the Sirius red/fast green dye was then incubated with each 
sample for 30 minutes. Samples were rinsed with 0.5mL of PBS twice, and then 0.3mL of 
the dye extraction buffer was applied and pipetted briefly to mix. 100μL of the extraction 
dye was added to a 96-well plate and optical density was analyzed with the Synergy H4 
plate reader at 540nm and 605nm.  
To calculate the amount of collagen, the OD 540 value was corrected by subtracting the 
contribution of Fast Green at 540 nm, which is 29.1% of the OD 605 value. The color 
equivalence (OD values/μg protein) is 0.0378 for collagen and 0.00204 for non-
collagenous proteins at OD 540 and 605, respectively.   
Collagen (ug section⁄ ) =
OD 540 value −  (OD 605 value x 0.291)
0.0378
 




2.3.7 Stretch Device 
Hardware from a commercially available Flexcell® system (Flexcell® International 
Corporation, Burlington, NC) was interfaced with a vacuum pump from Parker Hannifin 
Corporation and a custom control code using National Instruments LabVIEW program to 
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cyclically strain a monolayer of cells. In brief, 70,000 LMCs (~7400 cells/cm2) were seeded 
into each well of the Uniflex® Culture Plate onto a rubber membrane treated with type I 
collagen. The plate was loaded above loading posts which allow the cells to be deformed 
in a uniaxial direction through the manipulation of a vacuum below the wells, see Figure 
5.  
 
Figure 5: (A) Stretch Device Schematic. (B) Alignment of F-actin fibers for stretch 
and non-stretched CL LMCs to axis of strain 
For all stretch experiments, the membranes which made the basement substrate of the 
LMCs were stretched to 7.5% elongation at 0.1Hz for 1 week. The deformation profile was 
roughly a square wave with up to 2% oscillation around the set vacuum pressure. This 
translates to about a 0.3% variation in the percent elongation (7.5% ± 0.3%). Ultimately 
there were four stretch conditions; Control Leg LMCs - Non Stretched (CNS) , Control 
Leg LMCs - Stretched (CS) , Wounded Leg LMCs - Non Stretched (WNS) , Wounded Leg 




Blebbistatin (Abcam), an inhibitor to myosin II, was added to the cell culture media (5μM) 
to determine the sensitivity of the cyclic stretch induced behavior changes to the cell-matrix 
adhesion. 
2.3.8 Actin Fiber Alignment 
Images were taken of the wells post stretching for 1 week. The wells were immediately 
fixed in 4% paraformaldehyde once the experiment finished and stained with a F-actin stain 
(Molecular Probes, Eugene OR). Each image was analyzed with a Matlab code that utilizes 
built-in functions to determine the magnitude and direction of a vector indicating the path 
of maximum intensity change. In practice, this gradient vector is oriented perpendicular to 
a fiber at any given point along the fiber. The direction of the vector is given as an angle 
from -180° to 180°, referred to as the intensity angle. We then calculated an alignment 
score for each pixel based on how well the intensity gradient vector aligned to an arbitrary 
angle from 0° to 90° using the following formula: 
𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒𝑖 =  𝑎𝑏𝑠(cos (𝐴𝑛𝑔𝑙𝑒 − 𝑎𝑏𝑠(𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝐴𝑛𝑔𝑙𝑒𝑖)) 




Values were normalized to the minimum score in any direction for the specific image to 
correct for slight variations in brightness from image to image.  
2.3.9 Statistical Analysis of Functional Cell Assays 
All data was tested using GraphPad prism software. Data was initially tested for normality 
using D'Agostino & Pearson normality test. The normality test revealed that the 
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alamarBlue results in the control leg LMCs cultured in the standard DMEM were not 
normally distributed. In addition, the alamarBlue and the collagen synthesis results for the 
wounded leg LMCs cultured in the low serum DMEM were not normal. Therefore, 
multiple one-way, nonparametric, Kruskal-Wallis tests were used to assess statistical 
differences for a single LMC type across the three media conditions. Dunn’s test was used 
to correct for multiple comparisons. Differences between CL and WL LMCs in a shared 
media conditions were tested with the Mann-Whitney test. 
2.3.10 Proteomic Analysis 
One well of LMCs from each stretch condition (CNS, WNS, CS, or WS) was collected at 
the end of 5 individual stretch experiments to be used as a sample for proteomic analysis, 
with the cells that made up these samples being derived from 3 different sheep. Each of the 
5 samples was run through the protocols listed below in duplicate.  To prepare samples for 
proteomic analysis, monolayers of LMCs were rinsed once with PBS and then trypsinized. 
The cell solution was centrifuged for 5mins at 4°C and 800RCF. The resulting cell pellet 
was re-suspended in PBS and then spun down again under the same conditions. After 
aspirating the PBS, the cell pellet was then suspended in 0.5mL of RIPA lysis buffer 
(Thermo Scientific) and incubated on ice for 30 minutes. After 30 minutes, the samples 
were centrifuged at 13,000-14,000 RPM for 10 minutes at 4°C. The protein containing 
supernatant was collected and the pellet of cell debris was discarded. Protein content of the 
cell lysate was measured using a microplate BCA protein assay kit (Thermo Scientific) and 
aliquots containing 20μg of protein were stored in a -20C freezer. 
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Proteins in the supernatant are reduced, alkylated and digested with trypsin according to 
the FASP protocol116.  The peptides were analyzed by high-performance liquid 
chromatography-coupled tandem mass spectrometry (HPLC-MS/MS), separated on a 2 
micron, 15 cm X 75 μm C18 column, and analyzed with a Q Exactive Plus mass 
spectrometer.   
2.3.11 Protein Identification 
The protein IDs were assigned by searching the raw files from each technical and biological 
replicate against the sheep (Ovis Aries) Swiss-Prot database (December 2017; 788 entries) 
after being filtered and “de novo” sequenced in Peaks 8.0 software (Bioinformatics 
Solutions, Waterloo, Canada).   The following search parameters were applied:  trypsin 
restriction for enzyme and one allowed missed cleavages.  The parent mass tolerance was 
set to 15 ppm using monoisotopic mass, and fragment ion mass tolerance was set to 0.05 
Da, for the samples run on a Q Exactive Plus mass spectrometer.  Carbamidomethyl 
cysteine (+57.0215 on C) was specified in PEAKS 8.0 as a fixed modification.  Methionine, 
lysine, proline, arginine, cysteine and asparagine oxidations (+15.99 on CKMNPR), 
deamidation of asparagine and glutamine (NQ-0.98) and pyro-Glu from glutamine (Q-
18.01 N-term) were set as variable modifications.  The results were validated using the 
FDR method built in PEAKS 8.0 and protein identifications were accepted if they could be 
characterized with a confidence score (-10lgP)>15 for peptides and (-10lgP)>15 for 
proteins.  The FDR for proteins was further adjusted to less than 1% (p<0.05) after 
removing contaminants like serum albumin, hemoglobin, keratins and immunoglobulin 
and further allowing a minimum of 1 peptide per protein.   An independent validation of 
the MS/MS-based peptides and protein identification was performed with the Scaffold 
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(version Scaffold_4.7.3, Proteome Software Inc., Portland, OR) using the compatible “. 
mzid” files exported from PEAKS 8.0. for each “control” and “wounded” stretched or non-
stretched lymphatic muscles samples.  The Scaffold built in option “MuDPIT” was used to 
combine multiple files from technical replicates for each sample defining the “control 
stretched or non-stretched” and “wounded stretched or non-stretched” samples (see 
Supplementary Table 1).  Peptide identifications were accepted if they could be established 
at greater than 95.0% probability by the Peptide Prophet algorithm with Scaffold delta-
mass correction. Protein identifications were accepted if they could be established at 
greater than 90.0% probability and contained at least 1 identified peptide. Protein 
probabilities were assigned by the Protein Prophet algorithm. Proteins that contained 
similar peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony as described originally elsewhere117,118. 
2.3.12 Label-free relative peptide quantification (LFQ) and analysis of differential protein 
expression profiles across the stretch and non-stretched control and wounded 
sample  
Label-free quantitative (LFQ) methods used the raw spectral data from parallel MS runs to 
determine relative protein abundances.  We used both “MS/MS (MS2) spectral counting” and 
“precursor MS1 area” methods for LFQ analysis and further contrasting the differentially expressed 
proteomic profiles across the control and wounded lymph (stretched or non-stretch) muscle 
samples.  The label-free quantification based on the precursor intensity (area) was 
performed using the quantification algorithm supported by the PEAKS Q module 
(Bioinformatics Solution Inc., version 8.0).  The data were filtered, smoothed, and aligned 
in retention time, followed by feature detection based on peak volume and isotopic 
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clustering using the algorithm of PEAKS 8.0.  An additional LFQ analysis using the 
spectral counts intensity (MS/MS or MS2) was employed for the same set of samples using 
the normalized weighted spectrum count option provided in “perSPECtives”, (version 
2.0.6, Proteome Software Inc., Portland, OR).  The corresponding “.mzIdentML” files 
generated in Scaffold (version 4.7.3) for each “control” and “wounded” in both “stretched 
and non-stretched” sample categories were imported in “perSPECtives” where the 
threshold of 1 unique peptide/sample and the significance level of P<0.05 were set up with 
the standard Benjamini-Hochberg procedure. 
The relative protein abundances were displayed as heat maps including representative 
proteins of each protein group after normalization of the corresponding weighted spectral 
counts using the built-in algorithm from “perSPECtives” (see Figure 5A and 10A).  Only 
proteins, which passed a selected significance statistical threshold (ANOVA, p<0.05 and 
FDR <1% for protein and peptide expression) and are shown in the representative heat 
maps. 
2.3.13 Gene ontology (GO), molecular and cellular pathways enrichment analysis 
The biochemical and cellular pathways together with the GO assignments were generated 
by the ingenuity pathway analysis (IPA; Ingenuity Systems, Redwood City, CA, USA) on 
the list of differentially abundant proteins extracted from LFQ analyses (weighted and 
normalized MS2 spectral counts generated in Perspectives software) and presented 
categorized in the Supplementary Table 2. Specifically, the experimentally determined 
protein ratios, quantified using ≥ 1 peptides/sample, were used to calculate the 
experimental fold changes by rescaling their values using a log2 transformation, such that 
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positive values reflected fold increases while the negative values reflected fold decreases.  
For network generation, datasets containing gene identifiers (gene symbols) for the 
“control” and “wounded”, for each “stretched” and “non-stretched” sample category 
samples were uploaded into the IPA application together with their rescaled log2 
transformation MS2 normalized spectral counts ratios.  The networks with qualified 
molecules were then algorithmically generated based on their connectivity index using the 
built-in the IPA algorithm.  The probability of having a relationship between each IPA 
indexed biological function and the experimentally determined genes was calculated by a 
right-tailed Fisher’s exact test.  The level of significance was set to a P-value of <0.05.  
Accordingly, the IPA analysis identified the molecular and cellular pathways from the IPA 
library of canonical pathways that were most significant to the dataset (-log (p value)>2.0).  
For the quantitative analysis of protein expression profiles, IPA assigned the “z-score” 
function to all eligible canonical and cellular pathways (where a “z<-1.5 represent 
significant down-regulation while a z>1.5 represent a significant up-regulation of the 
selected pathway) (Figure 10 and Appendix A). 
2.4 Results 
2.4.1 Characterization of the Primary Lymphatic Muscle Cell Line 
Lymphatic cells were isolated from the hindlimb of an adult sheep as outlined in the 
methods. As shown in Figure 6, the leg in which a section of a parallel lymphatic vessel 
had previously been resected is referred to as the “wounded leg” (WL). The contralateral 
limb was left uninjured and referred to as the “control leg” (CL). Cells usually began to 
migrate away from the vessel after 2-3 days in culture. Cells were initially identified 
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through morphology; LMCs which migrated off the vessel plated in the non-inverted 
configuration had a spindle like morphology while lymphatic endothelial cells (LECs) 
which migrated off the vessel plated in the inverted configuration had a cobblestone-like 
morphology. 
 
Figure 6: Isolation and morphological identification of lymphatic muscle cells (LMC) 
and lymphatic endothelial cells (LEC): MRI image of the lymphatics in the hindlimb 
of an adult sheep using a gadolinium contrast agent. There are two primary collecting 
lymphatic vessels that drain to the popliteal lymph nodes (LNs). A 1cm section of the 
caudal vessel in the “wounded leg” (marked with a “X”) was removed. The intact, 
cranial, lymphatic vessel in the wounded leg (WL) and the corresponding intact vessel 
in the control leg (CL) were isolated at day 42 following surgery and plated in our 
standard DMEM with 4,500 mg/L of glucose and 10% FBS to produce lymphatic cell 
lines. Primary LMCs began to migrate from the non-inverted vessel by day 2-3 and 
had a spindle-like morphology. Primary LECs had a cobblestone-like morphology 
and were identified using similar methodology to LMCs but the vessel was inverted 
before plating. Both lines formed a monolayer once passaged. Scale bar is 1mm. 
The purity of the primary lymphatic muscle line was determined using expression of four 
relevant proteins to differentiate endothelial cells from smooth muscle, cells as seen in 
Figure 7. Wells of lymphatic muscle cells were positive for smooth muscle actin (SMA), 
collagen type 1 (Col 1), and tropomyosin (TMy), while being negative for endothelial nitic 
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oxide synthase (eNOS). LECs were positive for eNOS while being negative for the other 
3 markers (Figure 7). The differing protein expressions indicate successful separation of 
LECs and LMCs through the culturing and expansion technique used.    
 
Figure 7: Purity of LMC and LEC lines derived from the control leg of adult sheep. 
CL LMC (left) had positive expression of smooth muscle actin (SMA) labeled red, 
collagen type 1 (Col 1) labeled magenta, and tropomyosin (TMy) labeled yellow after 
one week of culture. CL LEC (right) had positive expression of endothelial nitric 
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oxide synthase (eNOS) labeled green after one week of culture. Nucleus stained in 
blue. Scale bar is 0.25mm. 
2.4.2 Optimizing Growth Conditions 
The impact of changing levels of glucose and serum (FBS) within the DMEM on the 
phenotype of in-vitro cultured LMCs was systematically explored. Culture in low serum 
DMEM (LS DMEM), drastically impacted the phenotype of LMCs after two days. The 
cells took on a shorter spindle morphology and aligned less densely as seen by the SMA 
staining (Figure 8A & B). Low glucose DMEM (LG DMEM), had a negligible impact on 
morphology and cell density. Furthermore, metabolic activity and production of collagen 
were significantly reduced upon reducing serum concentrations but were unchanged when 




Figure 8: Impact of culture media on non-stretched CL and WL LMC phenotype. (A) 
CL LMC and WL LMC SMA expression depict shorter spindle morphology and (B) 
lower cell density after two day culture in low serum DMEM (LS-DMEM) with 0.2% 
FBS compared to standard DMEM (10% FBS, 4500g glucose/L) or low glucose 
DMEM (LG-DMEM) with 1000g glucose/L. (C) alamarBlue assay show reduction in 
fluorescence intensity and by extension, metabolic activity and (D) Sirius red/fast 
green assay show reduction in collagen production in CL and WL LMCs after two-
day culture in LS-DMEM compared to standard DMEM and LG-DMEM. Error bars 
reflect standard deviation. 
*: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 
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Despite similar cell densities (Figure 8B), wounded leg LMCs consistently had higher 
metabolic activity levels (Figure 8C) than CL LMCs, but their response to changes in the 
culture media followed a similar trend to the response of the control leg LMCs. The cellular 
source of the LMCs (WL vs. CL) had no measurable impact on expression of collagen after 
two-day cultures (Figure 8D).  
2.4.3 Cyclic Stretching Impacts Alignment and Viability of LMCs 
Cells were cultured in standard DMEM on the stretch device as shown in Figure 5A. After 
exposure to cyclic stretch for one-week, LMCs from control and wounded legs (CS and 
WS LMCs, respectively) were fixed and stained for F-actin (Figure 9A). Control leg or 
wounded leg LMCs that were not stretched (CNS and WNS LMCs respectively), did not 
align in any particular direction. When LMCs were stretched in media containing 
blebbistatin (abbreviated as “Bleb”), an inhibitor for myosin, there was not a dominant axis 
to which the cells regularly oriented. Images were processed and the extent to which all the 
fibers fell along a specific orientation was assigned a score as outlined in the methods 
section. Stretched LMCs cultured in standard DMEM were much more likely to be oriented 
in the 90o direction compared to non-stretched cells and this orientation was lost with 




Figure 9: Impact of cyclic stretching on the alignment and metabolic activity in CL 
and WL LMCs.  (A) Representative images of F-actin fiber orientation of stretched 
(CS) and non-stretched (CNS) CL LMCs and stretched (WS) and non-stretched 
(WNS) WL LMCs taken after 1 week. Scale bar is 0.25mm. (B) Quantification of F-
actin fiber alignment for stretched and non-stretched LMCs. Preferential orientation 
perpendicular to strain (along 90o axis) is shown by comparing alignment score at 2o 
to alignment score at 90o for WS LMCs (top bar) and CS LMCs (2nd bar). 
Comparisons along the side are between the CS vs CNS LMCs and the WNS vs WS 
LMCs respectively. Error bars reflect standard error. There was no significant 
difference in the response between control and wounded LMCs (C) Blebbistatin 
(5μM) inhibited preferential alignment along 90o axis after cyclic strain. Error bars 
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are removed for clarity. (D) Impact of cyclic stretching on metabolic activity of LMCs 
cultured in Standard DMEM, and DMEM supplemented with Blebbistatin (5μM). 
*: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 
Results of alamarBlue assay showed significantly reduced fluorescent intensity, metabolic 
activity by extension, in both CS and WS LMCs compared to CNS and WNS, respectively. 
Culture in media containing blebbistatin inhibited any difference between the cell groups 
and their response to stretching (Figure 9D).  
2.4.4 Phenotypic Impact of Cyclic Stretching 
Proteomic analysis reveals much about the changing phenotype of the LMCs in response 
to cyclic stretch. Oxidative phosphorylation and mitochondrial function are displayed as 
one of the major pathways up-regulated for CL LMCs in response to stretch (Figure 10). 
“ATP synthase F0 subunit” is one of the highest up-regulated proteins in CS vs CNS 
(characterized by more than eight-fold increase in the expression profile).  The F0 subunit 
of ATP synthase is a transmembrane, proton powered, rotating motor, which provides the 
energy to convert ADP to ATP in the F1 subunit. The IPA analysis of cellular networks 
identified the increased in cellular spreading, transport of metals and organ degeneration 
up-regulated in the CS vs CNS (z>1.5 and orange/red color). By contrast, the down-
regulated cellular pathways in the CS vs CNS (z<-1.5 and blue/green color) identified the 
development of connective tissue together with cellular proliferation. Elevation of proteins 
such as cathepsin B (CTSB) and cathepsin D (CTSB) contribute to pathways associated 
with tissue degeneration. Reductions in the expression of tissue inhibitor of 




Figure 10: Comparative protein expression profiling of “control stretched” vs 
“control non-stretched” in the lymphatic muscle cells. (A) Heat map highlights the 
change in the protein expression profiles in the “control-stretched (CS))” relative to 
the “control non-stretched (CNS)” lymph muscle cells. (B) Oxidative phosphorylation 
and mitochondrial function is displayed as one of the major pathways up-regulated 
(red-color) in the CS vs CNS sample. The “expression value” associated with each 
protein found in the experimental data set presented in supplementary table 1 
highlights the “ATP synthase F0 subunit” as being top up-regulated protein in CS vs 
CNS (characterized by more than eight-fold increase in the expression profile). (C) 
The IPA analysis of cellular networks identified the increased in cellular spreading, 
transport of metals and organ degeneration up-regulated in the CS vs CNS (z>1.5 and 
orange/red color). By contrast, the down-regulated cellular pathways in the CS vs 
CNS (z<-1.5 and blue/green color) identified the development of connective tissue 
together with the cellular proliferation. The proteins in red and green had a 
significantly up- or down-regulated expression (p < 0.05), respectively. The shape of 
symbols denotes the molecular class of the proteins. A solid line indicates a direct 
molecular interaction, whereas a dashed line indicates an indirect molecular 
interaction. 
As a result of stretch, specific functional pathways associated with protein trafficking, 
carbohydrate metabolism, cell death/survival, and others were determined for stretched or 
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non-stretched CL LMCs (CS vs CNS). The up or down-regulation of specific proteins 
associated with these functions are outlined in Figure 11. 
 
Figure 11: Protein networks significantly regulated (p< 0.05) in the “control 
stretched” relative to the “control non-stretched” lymph muscle cells. The proteins 
were analyzed by Ingenuity Pathways Analysis (IPA, Ingenuity Systems) to determine 
the cellular pathways impacted by the stretched conditions relative to the non-
stretched control in the lymph muscle cells. (A) Significantly regulated protein 
networks (p< 0.05) in the “stretched control (CS)” relative to the “non-stretched 
control (CNS)” lymph muscle cells are displayed as IPA predicted diseases and 
cellular functions map using the z score (down-regulated corresponding to z>-1.5 and 
blue color; up-regulated, corresponding to z>+1.5 and orange color). The size of each 
rectangle is proportional with the value of the z score associated to a specific pathway. 
(B) Increased (z>2.0) organismal injury, cell necrosis, transport of metals and cell 
spreading are the main cellular pathways characterizing the “CS” vs “CNS” system. 
(C) IPA predicted also a decreased (z>-2) in the lipid metabolism, molecular transport 
and small molecule biochemistry together with a decreased in the proliferation of 
lymphocytes and development of connective tissue characterizing the cellular 
pathways down-regulated in the CS vs CNS. 
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As outlined previously, both CL LMCs and WL LMCs generally become less active and 
more aligned in response to cyclic stretch, but notably the WL LMCs were found to 
maintain higher levels of oxidative phosphorylation and mitochondrial dysfunction after 
one week of stretch (Figure 12).   
 
Figure 12: Quantitative analysis of protein expression profiles in the WS vs CS 
samples. The main canonical pathways affected by the top 105 protein genes 
presented in the supplementary table 2 for the WS vs CS samples were subjected to 
the analysis by IPA algorithm. The % of total molecules up- (light gray) or 
downregulated (dark grey) in each pathway are displayed. White is the total number 
of proteins in each pathway; which does not appear in our proteome. Each of the 
square dots on the histograms correspond to the -log(p-value), which act as a scoring 
function associated with each pathway and reflect the confidence of having the 
selected number of identified proteins IDs fitted to the IPA Knowledge-based 
canonical pathways.    
Comparing stretched WL and stretched CL LMCs, the stretched WL LMCs are subjected 
to some biochemical and cellular changes characterized by significant changes in functions 
related as cell growth, survival, movement, and free radical scavenging (Figure 13A). 
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Figure 13 B&C indicate proteins contributing to a down-regulation in cellular movement, 
ions transport and homeostasis and significant up-regulation in some metabolic pathways, 
related to the generation of energy from lipids and nucleotides as well as activation of 
reactive oxygen species (ROS) and regulation of ROS (Figure 13). 
 
Figure 13: Protein Expression and protein networks of the WS vs CS samples. (A) 
Top protein hits characterized by at least 1.5-fold up- or down-regulation in the WS 
vs CS samples are displayed together with the molecular and cellular functions 
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predicted by IPA to be affected by changes in these protein expression profiles. (B) 
Significantly down-regulated protein networks (p< 0.05) in the “WS” relative to the 
“CS” lymph muscle cells are displayed as IPA predicted diseases and cellular 
functions using the z score (down-regulated corresponding to z<-1.5 and blue color). 
(C) Significantly up-regulated protein networks (p< 0.05) in the “WS” relative to the 
“CS” lymph muscle cells are displayed as IPA predicted diseases and cellular 
functions using the z score (up-regulated corresponding to z>1.5 and orange color). 
By normalizing the signaling expression of the WL LMCs by the CL LMCs expression we 
can further demonstrate the distinct response of WL LMC to stretch when compared to 
control cells (Figure 14). Overall, proteomic analysis indicates that wounded stretched 
sample are predicted to be subjected to the loss of many intracellular signaling pathways 
responsible for preserving the ability of cells to move, proliferate or perform the normal 
metabolic reactions.  Figure 14 outlines variably expressed proteins and canonical 
signaling pathways. Remarkably, the wounded and stretched state (WS) was characterized 
by a significant fivefold down-regulation of stratifin (SFN) (Figure 15 A&C), an adapter 
protein implicated in the regulation of a large spectrum of both general and specialized 
signaling pathways, including Phosphoinositide 3-kinase (PI3K) and Protein Kinase A 
(PKA) signalling24.  In addition, at least a threefold down-regulation of myosin light chain 
kinase was induced in the WS as compared with the WNS lymph muscle cells (see 
expression profiles in Figure 15 F).  Another important change induced in the WS samples 
was the threefold down-regulation of the ATP synthase F0 subunit (Figure 14C) that 
suggests impairment in the mitochondrial ability to couple ATP synthesis with the 




Figure 14: Comparative protein expression profiling of “wounded/control stretched” 
vs “wounded/control non-stretched” in the lymphatic muscle cells. (A) Un-biased, 
non-clustered heat map generated in “perSPECtives” using the normalized weighted 
MS/MS spectral counts highlighting the change in the protein expression profiles in 
the stretched (CS) and non-stretched (CNS) controls vs stretched (WS) and non-
stretched (WNS) wounded lymph muscle cells. (B) IPA generated comparison of the 
canonical biochemical pathways characterizing the WNS relative to the WS samples, 
each normalized to the corresponding controls (CNS and CS, respectively). 
Significantly regulated protein networks (p< 0.05) in the “non-stretched WNS” 
relative to the “stretched WS” lymph muscle cells are displayed as a heat map using 
the z score (down-regulated corresponding to z<-1.5 and blue color; up-regulated, 
corresponding to z>+1.5 and orange color). (C) Comparisons of other cellular and 
molecular pathways predicted by IPA display the oxidative 
phosphorylation/mitochondrial function and IGF-signaling as the major possible 





Figure 15: Detailed protein expression profiles analysis inside the biochemical 
pathways displayed in Figure 14B. (A) Up- regulation of protein kinase A signaling 
in the WNS conditions as compared with WS (arrow and expanded table). (B) 
Similarly, the details of the protein expression profiles inside the integrin signaling 
pathway, which activated in the WS vs WNS samples. (C) Up- regulation of 
PI3K/AKT signaling in the WNS conditions as compared with WS (arrow and 
expanded table). (D) Expression profiles inside the alpha- adrenergic signaling 
pathway which down-regulated in the WNS vs WS samples. (E) Up-regulation of 14-
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3-3-mediated Signaling in WNS vs WS samples. (F) Up-regulation of rho family of 
GTP-ase signaling in the WNS conditions as compared with WS (arrow and expanded 
table). 
2.5 Discussion and Future Work 
Studies have begun to show that collecting lymphatic vessels remodel during the 
progression of disease states such as lymphedema. Collecting vessels isolated from patients 
with advanced lymphedema have been shown to become stenotic in lymphedemic limbs, 
with severity of lumen stenosis related directly to the stage of lymphedema119. This wall 
thickening seems to be due to remodeling of the lymphatic muscle cells, increasing in both 
cell proliferation and collagen synthesis within the walls as well as changing the protein 
composition of myosin45. This study presents a platform to both study the functional and 
molecular implications of this remodeling and to induce some of the features of the 
remodeling phenotype for further exploration in-vitro. We were able to successfully isolate 
LMCs from a lymphatic dysfunction model and established that the LMC lines used for 
this study were free of eNOS expressing cells such as lymphatic endothelial cells. We 
demonstrate that LMCs’ behavior seems to change from a more quiescent phenotype to a 
more proliferative and active phenotype after vessel injury and that these differences persist 
in culture.  A more quiescent phenotype seems to be restored partly in culture under low 
serum, reducing the LMC’s metabolic activity, as indicated through the alamarBlue assay, 
and reducing the production of collagen. The LMC line derived from the wounded leg of 
the adult sheep seem chronically differentiated, expressing high cell metabolic activity. 
Functional assay results, in combination with elevated signaling pathways highlighted in 
the proteomic analysis, indicate the WL LMCs may be in a more dedifferentiated, 
proliferative phenotype. While collagen expression was not quantifiably higher, other types 
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of ECM protein synthesis and proteins integral to ECM remodeling should be explored in 
future studies. 
In alignment with other work in smooth muscle cells, LMCs were particularly 
sensitive to serum levels. Lymph is rich in a variety of growth factors, and lymph spillage 
in addition to bleeding following lymphatic vessel or node resection may in part contribute 
to dedifferentiating the LMCs surrounding lymphatic vasculature120,121. While very little 
has been published on the effect of growth factors on LMC, vascular smooth muscle cell 
(VSMC) are very responsive to components of serum such as platelet-derived growth 
factor and insulin-like growth factor (IGF), which have been shown to induce proliferation, 
and migration in VSMCs. VSMC proliferation is accompanied by a loss in contractile force 
generation and increase in ECM synthesis32,111,122. Our work demonstrates that reducing 
serum levels restores aspects of a quiescent phenotype, similar to what’s been documented 
with VSMCs in-vitro101. While growth factors have a beneficial effect on expansion of 
lymphatic endothelial cells, it is possible that their sustained release could impair LMC 
function and contractility, although such statements are currently speculative due to the 
lack of research currently published on LMC signaling. Targeted and strategically timed 
interventions to conserve or restore the contractile phenotype of LMCs may contribute to 
treating or preventing future lymphatic complications.    
Recent work has thoroughly explored the phenotype of LMCs after being cultured in 
hyperglycemic and hyperinsulinemic conditions123. As the LMCs developed a resistance 
to insulin they also developed significant impairment to glucose uptake, mitochondrial 
function, ATP production, and other functional changes. The results from our study are 
largely in agreement with these findings as the response to changing glucose levels that 
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were previously observed were only apparent in the presence of insulin. Otherwise, the 
LMCs behaved quite similarly, regardless of glucose concentration in the media. Initially, 
introduction of high glucose media (25mM) lead to a short-term increase in glucose uptake, 
but glucose uptake lowered to initial rates within one-hour. This is slightly divergent to 
early work that explored in-vitro VSMC response to high glucose concentrations, which 
demonstrated that glucose levels alone lead to cell cycle progression and growth124,125. 
Exposure to cyclic stretch has been demonstrated to have a complex impact on 
VSMC phenotype 90 and this seems to hold  true for LMCs as well. Cellular response and 
sensitivity to stretch depends on many factors including the magnitude and frequency of 
elongation, loading profile, coating of the wells, direction of the strain, duration of stretch, 
and the phenotypic state of the cell prior to loading90. A notable study showed that by using 
a stretching waveform that replicates the heart pressure waveform proliferation was 
actually inhibited by cyclic strain126, despite purely sinusoidal strain typically enhancing 
proliferation in the majority of other 2D cyclic stretch studies127–129. With this in mind, our 
study attempted to design a waveform that was reflective of lymphatic physiology through 
choosing a frequency of 0.1 Hz and a percent elongation of 7.5%. These values reflect 
commonly reported of frequencies of lymphatic pumping in-vivo130 and the passive 
diameter changes from pressurizing an isolated collecting vessel from low pressures 
(~2cmH2O) to high pressures (≥6cmH2O)
131. Furthermore, the initial phenotype of a cell 
strongly influences its response to stretch. We demonstrate a notable differential response 
to stretch of the CL LMCs compared to WL LMCs, presumably due to different phenotypes 
of the LMCs prior to stretch, a phenomena noted in VSMCs as well132.  
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Proteomic analysis of the CL LMCs and their response to cyclic stretching outlined in 
Figure 12-Figure 14, under normal conditions LMC are more quiescent and contractile than 
the LMC derived from vessels that have undergone active compensation due to a lymphatic 
injury. Higher expression of signaling pathways associated with oxidative phosphorylation 
and insulin-like growth factor-1 in WL LMCs, regardless of stretch, indicate that the 
differentiation of the WL LMCs in response to a local injury persist 6 weeks after the initial 
insult and are maintained even after several passages in vitro (Figure 14C). Both of these 
pathways have been found to be critical to the growth, proliferation, and survival of 
VSMCs32,122,133,134. This, in part may explain the increased sensitivity of CL LMCs to tissue 
degeneration and apoptosis in response to stretch (Figure 13). Furthermore, the WL LMCs 
consistently expressed lower levels of α-adgrenergic signaling proteins (Figure 14B), a 
pathway critical for regulation of vascular tone and constriction of vascular smooth 
muscle135. In response to stretch, WL LMCs down regulate MLCK, which may be 
correlated with a weaker contractile state and increased migration or growth41. The changes 
in PKA signaling further support this notion as PKA signaling has been found to inhibit 
proliferation in response to vascular injury in VSMC136. Down regulation of PKA signaling 
in the WL LMCs (Figure 14B) further indicate a commitment to growth, a common 
reaction to vessel damage, in response to cyclic loading.  
Given the unique phenotype and function of LMCs, it is still unclear exactly how LMC 
remodeling impacts the unique lymphatic role of fluid drainage and immune cell 
regulation. Characterization of this sheep wound model in-vivo and the functional impact 
on intact lymphatic vessels will be the focus of future studies from our lab. Future 
experiments can build on this stretch platform to see how LECs influence LMC response 
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to stretch and to look for specific signaling pathways that can be interrupted to promote a 
specific response.  This platform and the established findings provide a framework to begin 
to explore how interventions to maintain or restore a given LMC phenotype in the presence 
of pathological cues. The effect of interventions adopted from vascular research, such as 
rapamycin or calcium channel agonist, on LMCs can be effectively and systematically 




CHAPTER 3. CHARACTERIZE SPROUTING 
LYMPHANGIOGENESIS SENSITIVITY TO EXTRACELLULAR 
MATRIX PROPERTIES USING A MODULAR 
POLY(ETHYLENE GLYCOL) (PEG) HYDROGEL. 
3.1 Overview 
Objective: After significant lymphatic damage, it is unclear how damaged collecting 
lymphatic vessels adapt and/or integrate back into the larger lymphatic network. Recent 
work has demonstrated that segments of lymphatic collecting vessel can be cultured within 
collagen gels. This causes lymphatic endothelial cells to proliferate from the vessel 
segment in a sprouting morphology. To engineer a regenerative scaffold to support 
collecting vessel regrowth, we have isolated and cultured segments of collecting lymphatic 
vessels within poly(ethylene glycol) (PEG) hydrogels with tunable properties to study the 
independent contributions of the physicochemical matrix properties to lymphatic collecting 
vessel regeneration.   
Methods: Modular, vessel-encapsulating hydrogels were formed using a four-armed PEG 
macromer with maleimide groups at each terminus (PEG-4MAL) that are conjugated with 
cysteine-containing ligands and crosslinker. Lymphatic collecting vessels downstream to 
the lungs were isolated and then segmented into 1-2 mm segments and individually 
encapsulated into PEG-4MAL hydrogels. We examined the response of sprouting 
lymphangiogenesis to the stiffness, adhesive peptides, and protease dependent 
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degradability of the PEG and compared them to the response of segments cultured within 
native collagen type I gels of various concentrations.  
Results: Fully degradable gels that were 10% PEG-4MAL and presented 2.0 mM RGD 
maximized branch length and branching number in PEG gels. Proliferation of cells 
occurred in both collagen gels and synthetic PEG-4MAL gels, with cells growing from the 
implanted vessel more rapidly in the collagen gels. Sprouts in the synthetic PEG-4MAL 
were more organized than in collagen and co-stained for ENOS, VEGFR-3, and SMA. The 
optimized gel was then used to demonstrate that sprouting lymphangiogenesis is sensitive 
to drugs used clinically in cancer chemotherapy and in lymphatic overgrowth syndromes 
in a concentration dependent fashion. These PEG gels were demonstrated to support the 
culture of lymphatic malformation tissue, where the clinical therapeutic rapamycin had a 
concentration dependent inhibition of cellular activity. 
Conclusions:  The properties of these synthetic hydrogels can be independently tuned, 
allowing greater control over the tissue microenvironment. We demonstrate the lymphatic 
collecting vessels are sensitive to the properties of extracellular matrix such as the relative 
stiffness, degradability, and adhesive peptides and that sprouting is optimized in a 10% 
PEG -2mM RGD gel compared to other tested formulations. Finally, a novel tissue-on-a-
chip platform of lymphatic malformations with patient-derived tissue is presented for 
probing the tissue response to rapamycin treatment.  
3.2 Motivation and Background 
Functional lymphatics are critical for proper fluid homeostasis, immune trafficking, 
and organ function. For example, appropriate integration of lymphatics have been found to 
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be important for mediating the initial inflation of postnatal lungs137 and influence the 
success of transplanted organs such as lungs or kidneys138–140. Despite their importance, 
our understanding of how lymphatics naturally repair after injury and respond to 
environmental cues in-vivo is lacking. As previously outlined, lymphangiogenesis is the 
process by which lymphatic endothelial cells (LECs) proliferate and form new vessels. 
Lymphangiogenesis has many parallels to angiogenesis, the formation of new blood 
vessels, and is promoted and inhibited by many of the same growth factors and signaling 
as the blood vasculature58,72. Unique to the lymphatic endothelial cells is a high surface 
expression of vascular growth factor receptor 3 (VEGFR-3), which binds most efficiently 
to its primary ligands, vascular endothelial growth factor C & D (VEGFC VEGFD)63,141,142. 
Unfortunately, naturally occurring lymphangiogenesis in response to inflammatory cues 
has often been show to worsen lymphatic dysfunction, in part by producing highly 
permeable, dysfunctional, initial lymphatics61,143,144. Examination of other environmental 
cues can allow for the promotion of lymphangiogenesis in the absence of other 
inflammatory signaling and independent of VEGFC to allow for finer control of the rate of 
lymphangiogenesis and the phenotype of the proliferating LECs.  
Most work elucidating the molecular mechanism regulating lymphangiogenesis ex-
vivo have cultured isolated LECs either in 2D culture or in collagen gels63,145–148. These 
studies have successfully showed novel pathways, such as the Notch signalling pathway, 
or signalling proteins involved in lymphangiogenesis63,145 as well as the role of interstitial 
flow149. While impactful, these assays have several limitations. Most commercially 
available LEC lines are derived from initial lymphatics and there is evidence that LECs 
lining a lymphatic collecting vessel are functionally distinct from LECs that compose the 
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initial lymphatics. This includes a downregulation of LEC specific markers such as Lyve-
1150,151. Therefore, lone culture of LECs derived from initial lymphatics are phenotypically 
distinct and may behave differently then LECs of the collecting vessel wall. Furthermore, 
culture of LECs alone prevents the study of how signalling between other cells of the 
collecting vessel wall influence lymphangiogenesis and repair mechanisms. While strides 
have been made in our understanding of mature collecting vessel formation in the 
developing embryo152–155, in the context of postnatal lymphangiogenesis it is unclear if and 
how sprouts mature to include muscle cell coverage and valve development. 
Lymphangiogenesis originating from an injured collecting vessel is likely in the surgical 
model of lymph node resection, but this condition has not been well studied ex-vivo. This 
requires researchers to recreate the signalling between the LMCs and LECs, as well as 
other unique cell populations and components that make up the collecting vessel walls.  
Some studies have begun exploring sprouting lymphangiogenesis in response to 
collecting vessel injury. In these studies, a segment or “ring” of a mature lymphatic 
collecting vessels can be cultured within hydrogels. Most studies with this approach have 
been done with a ring of the lymphatic thoracic duct cultured in collagen gels57,156. This 
collecting vessel approach allows us to examine the role of multicellular signalling on the 
rate and behaviour of sprout formation. Though few in number, these studies have shown 
the importance of matrix metalloproteinases, growth factors and their inhibitors in sprout 
formation in lymphatics vasculature.  
While relatively new to the lymphatic community, a similar assay has been done to 
explore angiogenesis from blood vasculature for decades. The arteriole ring assay has 
contributed much to our understating of sprouting angiogenesis and the formation of new 
 
 56 
blood capillaries from existing vasculature. In this assay a segment of artery is implanted 
within a hydrogel, such as collagen or Matrigel, and typically cultured for 6-10 days. This 
assay combines the repeatability of in-vitro experiments while allowing multi-cell 
signaling making it more relevant to the sprouting process in-vivo. These studies have 
shown how branching is dependent on contributions from a variety of cell types and 
processes to degrade the surrounding matrix and promote mature, lumen forming, 
sprouts157–160. Sprouting occurs most consistently from damaged areas of the vessel, with 
uninjured sections or the arterial ring being more quiescent161. In addition, sprouting occurs 
consistently even when the vessel is significantly damaged, with only full denudation of 
the endothelial cells typically inhibiting sprouting.  The type and properties of ECM plays 
a large role on sprouting angiogenesis for two major reasons. First, the ECM composition 
plays a role in what proteases will be able to degrade the matrix allowing migration and 
proliferation of cells162. In addition, the integrin/ligand specific binding and consequent 
mechanotransduction feedback are critical for influencing the behavior and function of the 
sprouts163. Sprouts are generally broken into two states of the endothelial cells, tip or stalk 
cells. Tip cells are along the leading edge and are more migratory than proliferative. Stalk 
endothelial cells are more proliferative and less migratory and begin to form early lumens 
in these assays. Stalk regions of sprouts typically have pericyte cell coverage offering 
structural stability164. 
Culture of segmented lymphatic collecting vessels within collagen type I based 
hydrogels has been useful but is inherently limited.  The properties of a collagen gel, such 
as stiffness degradability and availability of matrix binding sites, are all linked to the 
collagen density and therefore it is impossible to study the impact of these properties on 
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growth independently. Thus, we have implemented a poly(ethylene glycol) (PEG) based 
hydrogel to manipulate the microenvironment of lymphatic collecting vessel segments78. 
Specifically, modular, vessel-encapsulating hydrogels were formed using a four-armed 
PEG macromer with maleimide groups at each terminus (PEG-4MAL) that are conjugated 
with cell adhesive peptides and crosslinker. These gels are unique in that the density of the 
PEG, degradability, and adhesive peptides within the gel can be manipulated 
independently78. The modular capability of the PEG gel system allows us to decouple these 
properties of the ECM. In other studies of this platform, the components and density of the 
ECM alone have a significant impact on the behavior of tissue through specific integrin-
ligand interaction89,7877165. Signaling cues from the ECM matrix properties can lead to 
drastic changes in the form and function of a cell77.  In this study we systematically explore 
how matrix stiffness, degradability, and adhesive peptides on the function and response of 
sprouts from embedded lymphatic collecting vessel segments.  
Once optimized to enhance lymphatic sprouting, we then demonstrate the use of this 
platform as an in vitro screen to assess the impact of a variety of drugs on lymphatic growth. 
This is done in two clinically relevant contexts: first we investigate the lymphangiogenic 
effects of chemotherapeutic compounds on collecting vessel sprouting; second, we test the 
mTOR inhibitor rapamycin on collecting vessel sprouting of both lymphatic vessels culture 
from segments from the rat as well as on freshly isolated human biopsies of lymphatic 
malformations, which is a rare lymphatic-specific overgrowth syndrome thought to be 
driven by somatic mutations in the PI3-AKT signaling pathway. Vascularization by both 
blood capillaries and lymphatics is critical to allow primary tumors to grow and eventually 
metastasize. While the target of chemotherapeutic drugs is typically the primary tumor, the 
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role of chemotherapy on lymphatic behaviour is an area of growing interest19,69,166,167. The 
capacity of these drugs to inhibit or promote “cross-talk” between the tumor and lymphatics 
is critical to better avoid metastasis to downstream lymph nodes, as well as to reverse the 
tolerogenic environment of the locally draining lymph node146,168–170. We hypothesize that 
our platform can be used to further explore the role of docetaxel and carboplatin, another 
common chemotherapeutic drug, on the lymphatic sprouting lymphangiogenesis 
phenotype.  
We also examine rapamycin, a molecular inhibitor of mTOR, which impacts cell 
cycle progression and cell function. Rapamycin, also known as sirolimus, has been shown 
to directly impact the phenotype of vascular smooth muscle cells (VSMCs) and keep the 
muscle cells in previously described “contractile phenotype” in-vitro. This state is 
associated with lower proliferation, ECM synthesis, and improved expression of contractile 
molecular mechanisms32,102,106. Due to the similar changes observed occurring to LMCs 
during lymphedema, rapamycin may be useful in understanding the phenotypic changes of 
these cells. More immediately relevant is the increasingly common use of rapamycin to 
treat rare lymphatic and other vascular malformations171,172.  While early clinical use has 
seemed promising at inhibiting unregulated lymphatic growth, the efficacy across the wide 
variety of clinical presentation, the long-term impact on lymphatic health, and what cell 
types within the LM are the primarily target are unknown. Early work in a mouse model 
of lymphatic dysfunction driven by overexpression of VEGF-C demonstrated that 
rapamycin reduces overexpression of VEGFR-3 and the lymphangiectasia by 76% within 
7 days171. We demonstrate that our gels can be used as a high throughput method to culture 
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human, clinical lymphatic malformation tissue in-vitro in order to assess the impact of 
rapamycin on growth and activity.  
3.3 Methods 
3.3.1 Poly(ethylene glycol) (PEG)Hydrogel Formation 
To prepare PEG hydrogels, PEG-4MAL macromer (MW 22,000; Laysan Bio) was 
dissolved in 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer (20 mM 
HEPES in DPBS, pH 7.4) at 2.5x the final density. Adhesive and cross-linking peptides 
were custom synthesized by AAPPTec. Adhesive peptides RGD (GRGDSPC), GFOGER 
(GYGGGP(GPP)5GFOGER (GPP)5GPC), RDG, or GAOGER were dissolved in HEPES 
at 10.0 mM (5X final ligand density) and mixed with PEG-4MAL at a 2:1 PEG-
4MAL/ligand ratio to generate a functionalized PEG-4MAL precursor. After at least 15 
min, the functionalized PEG-4MAL precursor solution was further diluted using HEPES 
buffer at a 3:1 functionalized PEG-4MAL/HEPES ratio. Bis-cysteine cross-linking peptide 
GPQ-W (GCRDGPQG↓IWGQDRCG; ↓ denotes enzymatic cleavage site) was dissolved 
in HEPES at 5X the density that corresponds to 1:1 maleimide/cysteine ratio after 
accounting for maleimide groups reacted with adhesive peptide. Non-degradable (or 0% 
degradable) gels were made by exchanging GPQ-W with the non-enzymatically 
degradable crosslinking agent, PEG-DT (1,4-dithiothreitol). 
3.3.2 Lymphatic Isolation and Encapsulation 
Isolation of Rat Lung Draining Lymphatic Vessels (LLV) 
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Lymphatic collecting vessels that drain downstream of the lungs, running alongside 
the left phrenic nerve, were isolated from surrounding soft tissue in the chest cavity of adult 
male Sprague Dawley rats. In brief, rats were euthanized and immediately shaved along 
the chest. The chest cavity was then carefully cut open and the lung and heart were gently 
pulled to the side, exposing the phrenic nerve located above the lungs. About 5-6mm of 
lymphatic collecting vessel that travels parallel to the nerve was mechanically separated 
from the surrounding fat tissue, taking care to keep the vessel from drying out by frequent 
application of Dulbecco’s Phosphate-Buffered Saline (DPBS). After being cleaned from 
surrounding tissue, the vessel segment was removed and transported to a petri dish of 
DPBS for further cleaning and to be cut into roughly 300-micron long segments. To form 
hydrogels, an individual vessel segment was carefully placed into a solution of the cross-
linking peptide in a 24 well plate. A solution of the adhesive peptide-functionalized PEG-
4MAL macromer was then mixed in and allowed to polymerize for 15 min before the 
addition of growth medium. All animal procedures were performed in compliance with 
procedures approved by the Georgia Institute of Technology Internal Animal Care and Use 
Committee (IACUC). 
Collection of Lymphatic Malformation Tissue 
All procedures involved with the collection of lymphatic malformation samples 
were done in accordance with the accepted protocols submitted to the Internal Review 
Board (IRB) of Emory University and Georgia Institute of Technology. In brief, LM 
patients underwent percutaneous sclerotherapy of their lesions in Interventional Radiology. 
This procedure was done as part of the patient’s routine care and not for research purposes. 
During the procedure, a tissue sample, one 18-gauge 2cm specimen, was taken for research 
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purposes. The tissue sample was not from discarded tissue.  Lymphatic malformation 
segments were immediately transferred into DMEM/F12 solution containing 1% 
penicillin-streptomycin (p/s) after biopsies were taken from patients. Samples were 
typically several centimetres in length with a diameter of about 0.8-1mm and segmented 
into sections about 0.5mm long. In total, sample from 4 patients contributed to the 
presented work. Patients exhibited LM in a variety of anatomical locations including the 
neck, arm, left axilla and upper abdomen. Three of the four patients had been treated with 
rapamycin for some period of time prior to tissue collection. There were 3 females and one 
male patient ranging in age from 17 months to 19 years old. 
3.3.3 Tissue Culture 
Culture Protocol for LLV During Optimization of PEG Hydrogel Properties 
Segments were cultured in our standard endothelial basal medium (EBM) 
formulation. This consisted of EBM (Lonza,) supplemented with 20% FBS, 1% penicillin-
streptomycin-amphotericin B (Gibco), 1% Glutamax (Gibco), 0.1% DBcAMP (Sigma), 
and 0.1% hydrocortisone acetate (Sigma). Vessel segments were cultured for a total of 7 
days and media was changed on days 3 and 5.   
Culture Protocol for LLV to Assess Rapamycin Sensitivity  
For lung draining CV experiments involving rapamycin (Sigma R8781), the 20nM 
or 100nM rapamycin suspended in EBM, was applied to cells starting either immediately 
after implantation (day 0) or on day 5 of culture. Control tissue segments were treated with 
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an equal volume of DMSO (0.1μL DMSO/1mL EBM) to control for the independent 
impact of DMSO on cell growth. 
Culture Protocol for LLV to Assess Chemotherapy Drug Sensitivity  
Lung draining CVs segments used for the chemotherapy experiments were cultured 
in the standard EBM formulation until day 5. At this point non-sprouting segments were 
discarded. Samples were treated with docetaxel (1μM in ethanol) or carboplatin (1μM in 
PBS) or in a vehicle control of ethanol.  
Culture Protocol for LM to Assess Rapamycin Sensitivity  
For lymphatic malformation tissue, samples were cultured in the standard EBM 
formulation until day 5. At day 5 the specified concentration of rapamycin or DMSO was 
applied to the sample and reapplied at day 8 before fixation at day 10. Samples that had 
not begun sprouting by day 5 were discarded. 
3.3.4 Live/Dead Assay 
Calcein-AM and Toto-3 (Thermo Fisher) were used as a live and dead stain, 
respectively, to determine the viability of the tissue within the hydrogel at day 7. Each stain 
was mixed with cell culture media at a 1:1000 ratio and incubated with the tissue samples 
at 37°C for 1 hour. Samples were rinsed with PBS before imaging via confocal microscopy 
followed by fixation in 4% paraformaldehyde (PFA) for 10 minutes. All stains were 
imaged with the same (5x) objective. Images that appear to vary in magnification are a 2x2 
stitched tile composition, altering the size of the image but maintaining the same resolution 
for analysis.   
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3.3.5 Sprouting Analysis 
Sprouting from vessel segments were analysed following the live/dead stain using 
image analysis code developed in MATLAB (Appendix B). Samples were imaged using 
confocal microscopy. This code binarized the max intensity projections of the live stain 
determined the sprout length and branching complexity. If samples did not test positive for 
the live stain they were not included in the sprouting analysis. The code requires the user 
to manually select the center of the implanted vessel segment and then set concentric 
squares around the selected point to determine the quantity of tissue along the perimeter. 
By assessing the percent of tissue vs blank space along the perimeter the max length of 
sprouts and number of individual sprouts could be assessed. 
3.3.6 Cellular Metabolic Activity 
Given the large size of the sprouting network for lymphatic malformation tissue, 
metabolic activity was used to assess the impact of rapamycin on cellular growth and 
viability. The reduction-oxidation indicator known as alamarBlue® (ThermoFisher) both 
fluoresces and undergoes a colorimetric change in response to cellular metabolic activity. 
Each well was incubated in media containing 10% alamarBlue® reagent for 2 hours. After 
the 2 hours, 100μL of the media from each well was transferred to a 96-well plate. The 
fluorescent intensity of each sample-including well was measured using a plate reader 
(Synergy H4) after excitation with a 562nm wavelength laser. 
3.3.7 Immunostaining and Imaging 
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Fixed tissue samples within the gels were permeabilized with 0.5% Triton-X for 20 
minutes and then rinsed 3 times. After the third rinse, samples were blocked for 1 hour in 
a phosphate buffered saline solution containing 10% goat serum and 2% bovine serum 
albumin. The blocking solution was then removed, and samples were incubated with 
primary antibodies suspended in a 2% BSA solution (1:200) were incubated with the 
samples overnight at 4C on a rocker.  The samples were then rinsed three times and then 
rocked in a solution of secondary antibodies (1:400) for two hours at room temperature. 
After a final three rinses the samples were then imaged using confocal microscopy.  
3.3.8 Statistics 
GraphPad Prism version 7.01 was used for statistical analysis. Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test were used for comparisons between multiple 
experimental groups at the end of each culture period. All analyses were considered 
statistically significant at p<0.05. Error bars on all data points are standard deviation. 
Grubbs test for statistical outliers was used to remove one outlier from the 1.00mg/mL 
collagen gel condition.  
3.4 Results 
3.4.1 Assessment of Sprouting Response in Collagen Gels of Various Concentrations 
Segments of lung-draining lymphatic collecting vessels were implanted into 
collagen gels at 4 different concentrations of collagen: 1.00 mg/mL, 1.87 mg/mL, 3.00 
mg/mL, and 3.50 mg/mL. Generally, as the collagen concentration increased the resulting 
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sprout length was reduced (Figure 16). The average number of sprouts was only 
significantly reduced at the highest tested concentration of 3.50 mg/mL. 
   
Figure 16: Impact of Collagen Concentration on Sprouting Phenotype.  
Representative images of collecting vessel segments sprouting at day 7 in A) 1.00 
mg/mL, B) 1.88 mg/mL, C) 3.00 mg/mL, and D) 3.75 mg/mL collagen gels, 
respectively. Images are of intracellular fluorescent calcein indicating live cells. Scale 
bar = 500μm. E) Collagen concentration of 1.00mg/mL had significantly increased 
sprout length compared to concentrations of 3.00mg/mL or 3.75 mg/mL. F) There 
was a significant decrease in the average number of sprouts 3.75mg/mL gels 
compared to 1.00mg/mL. Significance was determined via Kruskal-Wallis test 
followed by Dunn’s multiple comparisons.  
*: p<0.05 
3.4.2 Assessment of Sprouting Response in PEG Hydrogel Formulations 
Segments of lung-draining lymphatic collecting vessels were implanted into the 
hydrogels of different formulations. The sprout properties were quantified to determine 
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max length of sprouts and the average number of sprout branches formed moving away 
from the vessel core.  
LLV segments were sensitive to the weight percentage of PEG macromers within 
the synthetic hydrogel. The length of sprouts within the PEG hydrogel was maximum at a 
10% weight percentage compared to 6% or 12% weight percentage (Figure 17). The 
number of sprouts branching from the embedded segment were enhanced at tested values 
above 6%. All PEG hydrogels used to test various percentages of PEG density contained 
2mM concentrations of RGD, which facilitated cell adhesion within the gels and were 
crosslinked with the enzymatically degradable GPQ-W crosslinker. 
  
Figure 17: Impact of PEG Weight Percentage on the Sprouting Phenotype in fully 
degradable, 2mM RGD Hydrogels. Representative images of collecting vessel 
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segments at day 7 cultured in A) 6% PEG, B) 10% PEG, and C) 12% PEG gel 
conditions. Images are of intracellular fluorescent calcein indicating live cells. Scale 
bar = 500μm. D)10% PEG optimized the radial sprout length from imbedded vessel 
segments at day 7 compared to 6% and 12% PEG. E)10% PEG improved the average 
number of sprouts. Significance was determined via Kruskal-Wallis test followed by 
Dunn’s multiple comparisons.  
*: p<0.05, **: p<0.01 
LLV segments in PEG hydrogels with tethered RGD peptides, which facilitate cell 
adhesion and migration, exhibited significantly higher sprouting when compared to the two  
scrambled negative control peptides, RDG and GAOGER, that do not allow for cell 
adhesion (Figure 18). PEG hydrogels tethered with the collagen derived GFOGER peptides 
did not support the same length or complexity of branching sprouts, and in fact produced 
sprouting that was not statistically different from the scrambled negative controls. Notably, 
PEG gels with the scrambled peptides allowed for low levels of sprouting seen on day 7 of 
culture. All adhesive peptides were at a 2.0mM concentration within a fully degradable 





Figure 18: Impact of Adhesive Peptide Type on the Sprouting Phenotype in fully 
degradable, 10% PEG Hydrogels. Representative images of collecting vessel segments 
at day 10 cultured in A) 2mM RGD, B) 2mM GFOGER, C) 2mM RDG, and D) 2mM 
GAOGER conditions. Images are of intracellular fluorescent calcein indicating live 
cells. Scale bar = 500μm. The RGD adhesive peptide optimized the E) max sprout 
length and the F) average sprout number from the imbedded tissue on day 7 
compared the GFOGER adhesive peptide and the 2 scrambled, negative control 
peptides, RDG and GAOGER. Significance was determined via Kruskal-Wallis test 
followed by Dunn’s multiple comparisons. 
*: p<0.05, **: p<0.01, ***: p<0.001 
Concentration of RGD was gradually reduced from 2.0mM to 0.0mM. To maintain 
full crosslinking of maleimide groups, RDG was used to replace the RGD as the 
concentration was stepped down such that the total concentration of both peptides 
combined was always 2.0mM. All tested concentrations of RGD above 0.0mM had 
statistically equivalent levels of sprouting by day 7 (Figure 19). Sprout length and average 
number of sprouts were not significantly different at tested concentrations. All hydrogels 
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used to determine optimal RGD concentration were fully degradable and were 10% PEG 
by weight volume.  
   
Figure 19: Impact of RGD Concentration on the Sprouting Phenotype in fully 
degradable, 10% PEG Hydrogels. Representative images of collecting vessel segments 
at day 10 cultured in A) 0.5mM RGD, B) 1.0mM RGD, C) 1.5mM RGD and D) 2.0mM 
RGD conditions. Images are of intracellular fluorescent calcein indicating live cells. 
Scale bar = 500μm. There was no significant change in E) radial sprout length or F) 
sprout number at tested concentrations above 0.0mM RGD. Significance was 
determined via Kruskal-Wallis test followed by Dunn’s multiple comparisons.  
*: p<0.05, **: p<0.01 
Finally, the impact of gel degradability on sprouting phenotype was explored 
(Figure 20). By altering the ratio of the fully degradable, GPQ-W, crosslinker, with a non-
degradable, PEG-DT, crosslinker we could alter the overall degradability of the gel. Fully, 
100% degradable gels were crosslinked entirely with GPQ-W while 0% degradable gels 
were crosslinked with PEG-DT. Fifty percent degradable gels were crosslinked with a 1:1 
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ratio of GPQ-W and PEG-DT. The fully degradable gel allowed for significantly longer 
and more numerous sprouts than a 50% less degradable hydrogel or completely non-
degradable gel. This property was explored in 10% PEG hydrogels with 2mM RGD. 
 
Figure 20: Impact of Gel Degradability on the Sprouting Phenotype in 10% PEG – 
2mM RGD Hydrogels. Representative images of collecting vessel segments at day 10 
cultured in A) 0% degradable, B) 50% degradable, and C) 100% degradable 
conditions. Images are of intracellular fluorescent calcein indicating live cells. Scale 
bar=500μm. D) Lymphatic collecting vessels cultured with 0% of 50% degradability 
had significantly reduced max sprout length by day 7 compared to the fully (100%) 
degradable condition. E) Lymphatic collecting vessels cultured with 0% of 50% 
degradability had significantly reduced average number of sprouts coming from the 
implanted vessel segment by day 10 compared to the fully (100%) degradable 
condition. Significance was determined via Kruskal-Wallis test followed by Dunn’s 
multiple comparisons.  
*: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 
3.4.3 Phenotype of Segment and Sprouting Tissue 
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Compared to the collagen gels, sprouts in the PEG hydrogels appear to be more 
organized, with multiple cells aligning into a single sprout extension (Figure 21). Cells in 
the collagen gel do not appear to organize into any complex, organized, structures. 
Sprouting lymphatic segments were stained for a variety of markers to assess cell type and 
phenotype. Alpha-smooth muscle actin (SMA) should stain either LMCs or myofibroblast 
that reside within the wall, while vascular endothelial growth factor 3 (VEGFR-3) and 
endothelial nitric oxide synthase (eNOS) staining was used to identify lymphatic 
endothelial cells (LECs). In the collagen gel (1.88mg/mL), the vessel core remained 
positive for VEGFR-3 and eNOS positive lymphatic endothelial cells. While cells away 
from the vessel core were generally not eNOS positive in the collagen gels, they were 
generally positive for either SMA or VEGFR-3. VEGFR-3 and SMA cells were generally 
not organized along a “sprout” but spread out along the gel. In the 10% PEG – 2mM RGD 
hydrogels sprouts expressed eNOS at a much higher intensity and uniformity than in the 
collagen gel (Figure 21). In addition, the SMA, VEGFR-3, and eNOS positive cells 





Figure 21: Representative Stains and Images of Lymphatic Vessel Segments Cultured 
in hydrogels. A-D) Stains of vessel segments cultured in fully degradable, 10%PEG – 
2mM RGD hydrogels for nuclei (blue), α-smooth muscle actin (red), endothelial nitric 
oxide synthase (gray), and vascular endothelial growth factor receptor-3 (green), 
respectively. E-H) Similar staining for vessel segments cultured in collagen gels 
(1.88mg/mL). Scale bars=100μm  
3.4.4 Impact of Chemotherapy Drugs on Sprout Phenotype 
Lymphatic collecting vessels cultured in the fully degradable, 10%PEG – 2mM 
RGD, hydrogel conditions were cultured in the established endothelial basal media until 
day 5. At day 5, sprouting segments were treated with docetaxel (doc), carboplatin (carb), 
or a vehicle control as outlined in the methods until day 10. Docetaxel significantly halted 
lymphatic sprout growth (Figure 22). In contrast, carboplatin had no consistent impact on 




Figure 22: Impact of Chemotherapy Drugs on the Sprouting Phenotype in fully 
degradable 10% PEG – 2mM RGD Hydrogels: Representative images of collecting 
vessel segments at day 10 cultured in A) ethanol (vehicle control), B) docetaxel, and 
C) carboplatin conditions. Images are of intracellular fluorescent calcein indicating 
live cells. Scale bar = 500μm. D) Lymphatic collecting vessels cultured with docetaxel 
(1mM concentration) at day 5 had significantly reduced max sprout length by day 10. 
E) Lymphatic collecting vessels cultured with docetaxel (1mM concentration) at day 
5 had significantly reduced average number of sprouts coming from the implanted 
vessel segment at day 10. There was no impact on sprout length or number from 
treatment with carboplatin. Significance was determined via Kruskal-Wallis test 
followed by Dunn’s multiple comparisons. 
*: p<0.05, **: p<0.01, ***: p<0.001 
3.4.5 Impact of Rapamycin on Sprout Phenotype 
The mTOR inhibitor, rapamycin, was applied to this sprouting assay to determine 
its impact on the sprouting response (Figure 23). When gels were cultured with rapamycin 
(20nM) from day 0 to day 7, sprouting was largely inhibited with only a few, short sprouts 
emerging (D0R20).  Rapamycin at 20nM, but not 100nM, applied at day 5 reduced 
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continued sprout growth compared to vehicle-controlled segments by day 7 (D5R20 and 
D5R100 respectively). Only sprouting in the vehicle control and the D0R20 condition were 
statistically different.  
 
Figure 23: Impact of Rapamycin on Sprouting Phenotype in fully degradable 10% 
PEG – 2mM RGD Hydrogels: Representative images of collecting vessel segments at 
day 7 cultured in A) DMSO (vehicle control), B) 20nM of rapamycin from day 0 
(D0R20) C) 20nM of rapamycin from day 0=5 (D5R20), D) 100nM of rapamycin from 
day 5 (D5R100). Images are of intracellular fluorescent calcein indicating live cells. 
Scale bar = 500μm. E) D0R20 condition had significantly reduced max sprout length 
compared to control. B) D0R20 condition had a significantly reduced average number 
of sprouts coming from the implanted vessel segment compared to control and the 
D5R100 condition. Significance was determined via Kruskal-Wallis test followed by 
Dunn’s multiple comparisons.  
*: p<0.05, **: p<0.01, ***: p<0.001  
3.4.6 Culture of Lymphatic Malformation tissue in PEG Hydrogel 
Segments of lymphatic malformation tissue collected from human paediatric 
patients were cultured within the gels for 5 days in our EBM formulation. At day 5 
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sprouting segments were treated with various concentrations of rapamycin, an inhibitor of 
mTOR. Compared with the control, tissue treated with 100nM rapamycin had significantly 
reduced metabolic activity by day 10, but no effect was observed on tissue treated with 
20nM rapamycin (Figure 24).  
 
Figure 24: Lymphatic malformation tissue cultured in fully degradable, 10%PEG – 
2mM RGD hydrogels. Representative images of LM tissue at day 10 of culture. From 
day 5 until day 10 tissue was cultured with either A) DMSO (vehicle control), B) 20nM 
rapamycin (D5R20), or 100nM rapamycin (D5R100). D) Metabolic activity of LM 
tissue at day 10 in various rapamycin concentrations. Images are of an F-Actin stain 
in green and DAPI in blue. Scale bar = 500μm. Significance was determined via 
Kruskal-Wallis test followed by Dunn’s multiple comparisons.  
*: p<0.05  
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3.5 Discussion and Future Work 
Here we have further demonstrated the sensitivity of lymphatic health and function 
on the unique biomechanical cues of the microenvironment. We demonstrated that culture 
of implanted segments of lymphatic collecting vessels within synthetic PEG hydrogels 
produce an “organized” lymphatic network with cells within the sprouts staining for both 
SMA positive cells and eNOS/VEGFR-3 positive LECs. Furthermore, we systematically 
demonstrate that the binding cues and biomechanical properties of the synthetic PEG gels 
significantly alter the growth rate and abundance of lymphatic sprouts. 10% PEG 
hydrogels, associated with a Young’s modulus of 1.5kPa173, lead to a relative maxima in 
sprout length and branching compared to other stiffnesses. This is around the physiological 
stiffness for healthy lung tissue, with a reported stiffnesses between 1-5kPa174,175. In 
comparison, collagen gels (2mg/mL) have a young’s modulus of roughly 0.2kPa176 
stiffness and fibrotic lung tissue exceed 17kPa stiffness177. RGD adhesive peptides at a 
concentration of 1mM to 2mM facilitated the formation of an intricate lymphatic network. 
PEG hydrogels embedded with GFOGER or that were not fully degradable had 
significantly reduced sprouting. We show high levels of α-smooth muscle actin positive 
cells in our sprouts in both PEG and collagen hydrogel conditions. This has not been 
documented in similar studies using segments of mouse thoracic duct in collagen gels57. 
This could be due to a unique composition of lung draining lymphatic vessels or the media 
formulation they were grown in (Figure 25). Both LMCs and myofibroblasts are capable 
of expression αSMA178 and it is unclear which cell type is integrated in the sprouts in our 
hydrogel formulations. Finally, we demonstrated that this optimized PEG gel can be used 
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as a platform to explore the impact of drugs and on the function of healthy or pathological 
lymphatic tissue.  
 
Figure 25: Representative sprouting from various lymphatic tissues in variable media 
formulations culture in collagen gels. A) Mouse TD sprouting network after 9 days 
culture in 2mg/mL collagen gels with media containing 10% FBS. Modified from 
Bruyère, 2008. B) Mouse TD sprouting network after 7 days of culture in 1.88mg/mL 
collagen gels with media containing 10% FBS. C) Rat LLV sprouting network after 
7 days of culture in 1.88mg/mL collagen gels with media containing 20% FBS. C) 
Mouse TD sprouting network after 7 days of culture in 1.88mg/mL collagen gels with 
EBM-20% FBS. D) Rat LLV sprouting network after 7 days of culture in 1.88mg/mL 
collagen gels with media containing 20% FBS. 
We demonstrate that the synthetic RGD peptide allowed for the most robust 
sprouting phenotype. RGD is a fairly conserved adhesive peptide found in fibronectin, 
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vitronectin, fibrinogen, as well as others, and has been demonstrated to bind with high 
affinity to a variety of integrins179–181. For future work two integrins of interest that have 
been shown to bind to RGD are αvβ3 and α5β1 integrin for their demonstrated role in 
lymphangiogenesis or angiogenesis. As previously detailed, α5β1 has been shown to be 
upregulated in sprouting lymphangiogenesis of the airway75. The αvβ3 integrin has been 
shown to be upregulated in angiogenesis, and critical for lumen formation, but the specific 
impact on lymphangiogenesis has not been studied182. This work would imply that these 
integrins play a role in sprouting lymphangiogenesis but additional staining and blocking 
via antibodies during culture would be needed.  
Additional adhesive proteins within the serum and produced by synthetic muscle 
cells and resident fibroblasts of the collecting vessel wall are likely to become integrated 
into the gel during the 7-day culture. Deposition of adhesive proteins from these sources is 
likely what allows for sprouting lymphangiogenesis in the RDG and GAOGER containing 
hydrogels. RDG and GAOGER peptides have been scrambled in in order to significantly 
impair their binding affinity to any native integrin, but deposition of these binding proteins 
from the media could allow for the limited sprouting that is observed in these conditions. 
GFOGER, a binding region primarily expressed in type I and IV183, did not significantly 
enhance sprouting compared to the scrambled negative controls. GFOGER has been shown 
to bind with high affinity to α1β1, α2β1, and α11β1 intigrins184,185. Interestingly, activation 
of α1β1 and α2β1 integrins have been correlated with elevated lymphangiogenesis in the 
presence of tumors186,187, but it is unclear what the role of these integrins are during 
lymphangiogenesis in the absence of tumor cells. Binding motifs that form other common 
 
 79 
ECM proteins, such as laminin, or combining multiple adhesive peptides should be the 
focus of future work to determine novel or synergistic effects.  
In addition to seeing how properties of the surrounding matrix influence lymphatic 
tissue sprouting, this PEG gel platform allows for a reliable method to determine the impact 
of various small molecule regulators on lymphatic viability. We show how common 
chemotherapy drugs, docetaxel and carboplatin, impact sprouting lymphangiogenesis 
directly. Research on these chemotherapy drugs and lymphatics have primarily focused on 
how to target these drugs for lymphatic uptake and eventually into the lymph nodes to act 
on metastasizing tumors166,167,188. Recent work demonstrating that, in-vitro, docetaxel may 
improve the ability of tumor cells to invade through the lymphatics is important to consider 
as we continue investigating alternative delivery methods146. This change in permeability 
may also explain why docetaxel has been shown to transiently increase fluid retention in 
the limbs of some cancer patients189. We show that docetaxel has a significant impact on 
lymphangiogenesis in this assay, while carboplatin seems to maintain base levels of 
sprouting. Future work could focus on how culture with these chemotherapeutics impact 
tumor invasion or alters sprout junction permeability within our PEG sytem.  Furthermore, 
we demonstrate that, on healthy rat LLV, rapamycin reduces sprouting attained at day 7 
when added to the media at the time of tissue implantation. Two days of rapamycin 
application at 20nM or 100nM was not sufficient to elicit a measurable effect on sprouting 
but future work could look at later time points or increased concentrations. Based on the 
lymphatic malformation results, 5 days or culture with rapamycin was able to illicit a 
measurable reduction in metabolic activity of the embedded segments. In blood 
vasculature, rapamycin has been used to maintain VSMCs in a contractile phenotype in-
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vitro, partially inhibiting the increase in proliferation, migration, and matrix synthesis in 
response to 2-D tissue culture102,106. Clinically, rapamycin eluting stents have been 
successfully used to reduce restenosis, avoiding the invasive nature of synthetic vascular 
smooth muscle cells190. Due to a somewhat similar behaviour of lymphatic muscle during 
lymphedema, future work could explore if targeted rapamycin treatments could maintain a 
healthy, functional, collecting vessels under lymphedema-like conditions.   
Overall, there are many directions that this work could go in in the future. Quantifying 
sprout length and complexity gives us a limited understanding of sprouting. As previously 
mentioned, it has been shown that inflammatory induced lymphangiogenesis produces 
leaky lymphatic vessels and therefore optimizing sprout length and complexity may or may 
not be “ideal”. Future work should focus on examining the exact phenotype and functional 
capacity of theses sprouts. A gel formulation that maintains junction integrity of newly 
formed initial lymphatics or mediates remodelling and stenosis of collecting vessels when 
implanted in-vivo would have large translational impact in breast cancer related 
lymphedema. Lymphatic malformation tissue can be successfully cultured in these gels and 
we show how rapamycin impact malformation behaviour specifically, but the PEG 
hydrogel implemented was not formulated for malformation tissue specifically. It is 
currently unknown how ECM properties may impact lymphatic malformation behaviour 
and before we can fully explore therapeutic interventions for the LM phenotype, it is 
important to demonstrate that the cultured LM tissue is functionally similar to the initial 
biopsy. While rapamycin has been shown to be generally effective at inhibiting unregulated 
LM tissue growth, the permanency of its effect once removed is an area of interest that 
could be easily studied with this platform.   
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CHAPTER 4. UTILIZE ANIMAL LYMPHATIC DAMAGE 
MODELS TO STUDY PEG HYDROGEL FACILITATED 
LYMPHATIC TISSUE TRANSPLANTATION AND INFLUENCE 
OF PEG HYDROGELS ON LYMPHATIC FUNCTION AND 
REGENERATION FOLLOWING INJURY.  
4.1 Overview 
Objective: Determine the capacity of the 10% PEG – 2mM RGD hydrogel, characterized 
in chapter 3, to transfer healthy lymphatic tissue to a wound site and to enhance native 
lymphatic repair and regeneration mechanisms in a translatable animal model. 
Methods: To assess the capacity of PEG hydrogels to deliver lymphatic vessels, a popliteal 
draining collecting vessel was isolated from a ubiquitously expressing GFP rat and 
transferred to a non-GFP expressing rat where the local lymphatics had been resected. 
Lymphatic regeneration was monitored with non-invasive NIR imaging over the course of 
28 days and then engraftment of the donated tissue was determined through tissue staining. 
In addition, a separate rat model was used to assess the impact of PEG hydrogels 
implantation after axillary lymph node dissections (ALND). The impact of PEG alone was 
compared to autologous lymph node segment transplant back into the resection site after 
encapsulation in either the PEG or collagen gel. 
Results: PEG gels were capable of transferring collecting vessel segments into the 
lymphatic network upstream of the popliteal lymph node. Transferred tissue became 
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functionally engrafted into the host as shown by co-staining of fluorescently labeled lectin 
delivered via intradermal injection within GFP-positive lymphatic vasculature. In the 
ALND model there was an initial increase in lymphatic function at 1 week after lymph 
node removal followed by long term dysfunction of upstream collecting vessels at 4 weeks, 
even though there was partial regeneration of lymph draining tissues in the site where the 
node was removed. However, no biomaterial intervention significantly outperformed 
native repair mechanisms in the ALND model.  
Conclusions: PEG gels are a promising vehicle to transplant lymphatic tissue into an area 
of lymphatic damage. Further work to use the hydrogel platform in conjunction with 
growth factor delivery needs to be done to further encourage native tissue to engraft within 
the gel. There is also a pressing need to create and characterize a translationally relevant 
animal model, that has limited regeneration capacity, to assess the impact of PEG gels on 
the function of the remaining intact lymphatic vessels and the invasion of new lymphatic 
networks.   
4.2 Motivation and Background 
Lymphedema is a common side-effect of treatment for patients recovering from a 
variety of cancers including breast, prostate, and oral cancer. It is the blockage of lymphatic 
vessels, leading to fluid retention and swelling of the arms or legs. The exact pathogenesis 
of breast cancer related lymphedema (BCRL) following initial surgery is not fully 
understood, but it is believed that the severity of the surgery, in combination with the type 
and duration or cancer treatments increases the risk of eventual lymphedema 
development191. Two of the most promising emerging surgical therapies for lymphedema 
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are vascularized lymph node transfers or lymph node flap transfers. These techniques 
transfer one or multiple functional lymph nodes from one region of the patient into the 
dysfunctional limb or region. Early application and assessment of these techniques have 
had promising results permanently treating symptoms of lymphedema but did not work for 
all patients94,95,192,193.  Unfortunately, the molecular mechanisms that contribute to these 
beneficial outcomes are not well understood. It is unclear exactly how the lymph node 
reconnects to the local lymphatic network, if the full lymph node is needed or if any 
lymphatic tissue would be beneficial, or how we can enhance the success and integration 
rate. As researchers we must select the most appropriate animal models to begin studying 
these questions. 
The most commonly used animal model to study lymphedema is the mouse tail 
lymphedema model. This model has been incredibly useful to our understanding of the 
lymphatic system and disease pathology but remains limited in its translational 
applicability. The mouse tail is drained by two primarily lymphatic collecting vessels that 
run in parallel and a hexagonal crisscrossing of initial lymphatic vessels. In the tail 
lymphedema model a ring around the mouse tail is cauterized, damaging initial lymphatic 
capillaries and the collecting vessels without damaging the major veins and artery of the 
tail. As a result, the tail of the animal swells significantly (2-3 times the typical diameter at 
the peak of swelling) 93,194,195. This model has been used to show the importance of VEGF-
C in swelling management51,60,143 and demonstrate the role of fibrosis and various immune 
cells at regulating swelling outcomes48,49,93. One drawback to this model is that swelling in 
all animals, even without intervention, is self-resolving. Unlike the presentation of 
lymphedema in humans, swelling in the mouse tail occurs immediately after surgery and 
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is not chronic.  Below we outline alternative animal models to this full tail lymphatic 
ligation model that we use to inform the studies outlined later in this chapter. 
A criticism of the tail model with respect to its relevance to breast cancer related 
lymphedema (BCRL) in humans is the fact that all collecting vessels of the tail are severed 
during the surgery, leaving no intact functional vessel to drain the distal limb where 
swelling occurs.  In BCRL, some functional lymphatics that drain the arm remain following 
lymph node biopsies and subsequent cancer treatments196.  To address this, novel animal 
models for lymphedema are being developed which better recreate the conditions that 
cause BCRL in humans and the chronic symptoms found in humans. For example, a single 
vessel ligation has been used in the tail lymphedema model and has been used to 
characterize the functional response of the intact collecting vessel after local damage to the 
lymphatic network47. This model revealed that the intact vessel has reduced contractility 
following isolation of the parallel lymphatic vessel that persists long after swelling 
resolves. This model would allow us to look at how transplanting tissue or biomaterials 
after injury of a single vessel improves regeneration and impacts function of nearby intact 
lymphatics. However, the taut skin cannot be easily sutured close making it a challenging 
location for transplantation. The sheep model outlined in chapter 2, presents results similar 
to the single lymphatic vessel ligation tail model, and would allow for easy transplantation 
of biomaterials, but large animal models have a low throughput and require special 
accommodations which were not feasible for this study.  
Tumor draining lymph nodes typically reside in the axillar of breast cancer patients, 
and therefore are typically removed when primary tumor metastasis is assessed. Another 
promising animal model for studying lymphedema progression and onset is the removal of 
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axillary lymph nodes.  In rats, it was found that lymphatic vessels are chronically impaired 
following axillary lymph node dissection (ALND), months after the initial swelling has 
resolved. Oxazolone, which is used as a model of contact hypersensitivity due to repeated 
application inducing fibrosis when applied to the skin, was applied repeatedly to the 
forelimb of rats 2 months after surgery. Animals that had undergone ALNDs had 
significantly increased swelling compared to unoperated controls, despite the absence of 
physical symptoms at that time oxazolone application commenced. This would imply 
chronic, underlying dysfunction of the lymphatics needed to drain the limb which is only 
seen once the limb is challenged with a new inflammatory insult. This is much more in line 
with our current understanding of what happens in human patients41,42. Mouse models of 
ALND have also shown that VEGF-C delivery can enhance incorporation of a transferred 
lymph node60.  
In addition to working with a clinically relevant animal model, we sought to acquire 
preclinical data on the efficacy of PEG hydrogels to enhance lymphatic regrowth and 
function following surgical damage. While certain therapies, such as the injection of 
collagen into wound sites, have been demonstrated to reduce negative symptoms of 
inflammation and swelling49,197 , the mechanism by which this impacts lymphatic repair, 
inflammation, and the functional response they elicit from intact lymphatics has not been 
thoroughly examined. Furthermore it is unclear if a whole lymph node must be transferred 
to achieve benefits, or if any healthy lymphatic cells/tissue would be beneficial, For 
example, cell transplantation of healthy human LECs into an animal model after surgical 
induction of secondary lymphedema showed reduced swelling and fibrosis as a result198. 
The goal of this study is two part: 1) To demonstrate that the synthetic PEG hydrogel 
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characterized in chapter 3 can be used to deliver lymphatic vessel segments into a host 
animal and become functionally incorporated.  2) Determine if the PEG hydrogels 
outperform natural healing mechanisms or alternative biomaterial approaches at preventing 
dysfunction of existing lymphatic vessels and promoting integration of transferred lymph 
node segments. To do this in a translationally meaningful way we first recreate the rat 
lymphatic dysfunction model via axillary lymph node dissections. We then measure the 
natural lymphatic responses to this surgical insult and compare it to three intervention 
conditions. We implant the degradable 10% PEG -2mM RGD gel with and without an 
imbedded lymph node segment, as well as a type I collagen gel containing a lymph node 
segment.   
4.3 Methods 
4.3.1 GFP Tissue Transplantation with PEG Hydrogels 
Surgical Procedure  
Ubiquitously green fluorescent protein (GFP) expressing Sprague Dawley rats 
(RRRC:0065 [SD-Tg(UBC-EGFP)2BalRrrc]) were purchased from the Rat Resource & 
Research Center. Animals were anesthetized via injections of ketamine (40mg/kg) and 
dexdomitor (0.13mg/kg) and the left hindlimb was shaved of hair. A near infrared (NIR) 
dye, conjugated to 20kDa PEG polymers, were injected into the footpad. Due to the size 
of the polymer this NIR tracer is drained from the footpad interstitium exclusively by the 
lymphatic system. Imaging through the skin revealed two lymphatic collecting vessels that 
drain lymph formed in the foot pad to the popliteal lymph node and travel parallel to the 
saphenous vein. A 1-2cm long segment of the two parallel collecting vessels was resected  
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proximal to the ankle (Figure 26). These vessels were segmented into 3-5mm long 
segments and stored in sterile saline solution. In non-fluorescent Sprague Dawley rats, the 
same segments of collecting vessel were isolated and discarded. One segment of the GFP 
expressing collecting vessel was placed along the lateral side of the saphenous vein where 
the host’s collecting vessel was removed. Ten microliters of 10%PEG – 2mM RGD gel 
was carefully polymerized over the vessel segment and the skin sutured close over the gel 
and wound. Gels were fabricated as outlined in section 3.2.1. The animals were risen with 
antisedan (1.3mg/kg) and carefully monitored following recovery. Lymphatic repair in the 
wound site was assessed using NIR imaging on days 7, 14, and 28 following surgery. This 
procedure was carried out on 2 adult male rats. All animal procedures were performed in 
compliance with procedures approved by the Georgia Institute of Technology Internal 
Animal Care and Use Committee (IACUC). 
Tissue Collection and Staining 
On day 28, the animal was administered an intradermal injection of fluorescent 
lectin, wavelength 649, that was passively drained by the lymphatics due to size exclusion 
from the blood vasculature. After 10 minutes, animals were then euthanized and the entire 
wound site, including the saphenous vein, was isolated and immediately frozen in optimal 
cutting temperature (OCT) compound. Tissue slices were stained with a nuclear DAPI 
stain, for GFP expressing cells, and VEGFR-3 expressing cells. Samples were fixed using 
a 4% paraformaldehyde (PFA) suspended in a physiological saline solution for 10 minutes 
then rinsed three times with phosphate buffered saline (PBS). Sections were permeabilized 
with a 0.5% Triton-X solution at room temperature for 10 minutes and rinsed again three 
times in PBS. Blocking of samples was done in a PBS solution containing 2% bovine serum 
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albumin, BSA and 10% goat serum for 1 hour at room temperature. Following this, primary 
antibodies for GFP and VEGFR-3, suspended in the 2% BSA solution (1:100), were 
applied to the samples for one hour on a plate rocker. The samples were rinsed in PBS (3x) 
before application of a fluorescent secondary antibody solution in 2% BSA (1:200) for 1 
hour at room temperature on a shaker. Samples were rinsed two times in PBS before 
imaging. Additional sections were also stained with isotype control antibodies for the GFP 
antibody (chicken IgY) and VEGFR-3 (polyclonal rabbit IgG). The maximum intensity 
from these controls were subtracted from the actual stains to eliminate background and 
non-specific fluorescence. 
4.3.2 Axillary Lymph Node Dissection Procedures  
Surgery and Conditions 
Axillary lymph nodes (ALNs) were isolated from adult female Sprague Dawley 
rats. In brief, a surgical incision through the dermis was made across the axilla of a rat. 
This exposes a fat pad in which the axillary lymph nodes reside. The axillary lymph nodes, 
as well as a short segment of the pre- and post- nodal collecting vessels, were isolated with 
care to minimize damage to surrounding muscle and tissue.  If a lymph node segment was 
to be returned to the wound site, one of the lymph nodes was stored in a sterile saline 
solution. All animal procedures were performed in compliance with procedures approved by 
the Georgia Institute of Technology Internal Animal Care and Use Committee (IACUC). 
There were 4 conditions in total to determine the impact of various interventions. 
The negative control animals simply had the axillary lymph node dissection (ALND) 
performed and immediately had the dermis over the isolation site sutured close.  The PEG 
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gel group (labelled as PEG) had 20μL of the fully degradable, 10%PEG-2mM RGD, 
hydrogel polymerized directly into the site where the nodes initially were located and then 
the wound was sutured shut. The final two conditions had a segment of one of the isolated 
ALNs encapsulated into 20μL of either a type-1 collagen gel (CG/LN) or the previously 
described PEG gel (PEG/LN). The collagen gel was at a concentration 1.85 mg 
collagen/mL. In total there were 5 rats in the ALND condition, 6 in the PEG/LN condition, 
4 in the PEG condition, and 4 in the CG/LN condition. 
Lymphatic Functional Imaging via Near infrared (NIR) Imaging  
The forelimb was shaved of hair before each imaging session. Anesthetized animals 
were injected with 15μL of NIR-labelled 20kDa PEG in either the foot-pad or between the 
fingers of the forepaw. The imaging window was downstream of the injection along the 
collecting vessels that drain the injection site. After a 5-minute adjustment period following 
the injection NIR images of dynamic lymphatic transport were captured at a rate of 10 fps 
with a 50ms exposure time for a total of 5 minutes. Lymphatic pumping measurements, 
such as contraction frequency and fluorescence transport (a proxy for lymph transport) 
were measured via a custom MATLAB code outlined in a previous publication130. In brief, 
the average fluorescent intensity of a small, manually selected, region of a collecting vessel 
could be calculated over time, with dips or peaks in fluorescence intensity corresponding 
with a contraction or an influx of lymph, respectively.  
Wrist Swelling Measurements 
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Accompanying each imaging session, outlined above, and including the day of the 
surgery, an image of the paw/wrist was taken with the stereoscope. The diameter of the 
wrist was manually recorded from each image. 
Oxazolone Application 
After two months of recovery from the initial ALND surgery, the rats were 
challenged with a topical oxazolone application. First, animals were sensitized by applying 
300µl of 2%oxazolone in ethanol to a 1”x1” shaved section of the abdomen using a 
micropipette. Animals remained anesthetized until the applied oxazolone had dried. 
Sensitization occurred on day 56. 
To initiate dermatitis, 300µl of a 1.6% oxazolone solution of acetone and olive oil 
(4:1) was applied to the shaved forelegs of anesthetized animals beginning on day 63. The 
oxazolone solution was applied to the entire foreleg up to the shoulder using a micropipette 
and allowed to dry before the rats regained consciousness. Oxazolone was applied again 
on day 66 and 70, 73, and 77.  
Terminal Procedures and Tissue Collection 
Following the final imaging session on day 98, which required an injection of NIR 
dye, animals were awoken from their anaesthesia and allowed to move around their cage 
for 20 minutes. Following this period, animals were euthanized and the brachial lymph 
node (BLN) and any dye containing tissues within the axillary pocket were isolated. The 
BLN and axillary tissue were imaged using the NIR scope and the intensity of NIR dye 




GraphPad Prism version 7.01 was used for statistical analysis. For the data grouped 
into a single experimental group a one-way ANOVA followed by Tukey’s multiple 
comparisons test was used to determine significant differences at different time points. A 
two-way ANOVA test followed by Sidak’s multiple comparisons test were used for 
comparisons between differemt experimental groups at each time point following surgery. 
Error bars on all data points are standard deviation. All analyses were considered 
statistically significant at p<0.05.  
4.4 Results 
4.4.1 Use of PEG Hydrogel to Implant Lymphatic Tissue for Lymphatic Repair 
A segment of GFP expressing collecting vessel was implanted into the wound site 
of a non-fluorescent host after the two lymphatic collecting vessels that drain the foot pad 
were resected (Figure 26 A). After just one week, lymph flow, as tracked with NIR dye, 
seemed to have been established through flow through a network of smaller collateral 
vessels. By day 28, flow through a single mature collecting vessel was restored across the 
wound site (Figure 26 B-E). During the injection on day 14 the needle hit a blood vessel 
and caused bleeding, which prevented drainage of the NIR lymphatic tracer to the 
collecting vessels downstream (Figure 26 D). On day 28, 20uL of fluorescent lectin was 
injected into the foot pad and drained into the lymphatics due to size exclusion from the 
blood capillaries. Imaging the fluorescent lectin through the skin matched perfectly with 
NIR fluorescence confirming lymphatic specific drainage. Skin above the wound site was 
carefully removed and tissue below the skin along the gold square was removed, sectioned, 
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and stained. The draining lymphatic collecting vessel was easily identified due to the lectin 
stain (Grayscale in Figure 26 G). GFP expressing cells had become incorporated in much 
of the vasculature including the saphenous vein (indicated with the red arrow). The 
draining lymphatic collecting vessel stained as GFP positive, but weakly for VEGFR-3 
(Figure 26 J&I).  
 
Figure 26: Representative images from the popliteal tissue transfer surgery. A) 
Brightfield image of rat hindlimb with exposed saphenous vein. The dashed yellow 
box is the approximate location along the hindlimb shown in panels B-F. B) 
Presurgical NIR imaging of the two collecting vessels running parallel along the 
saphenous vein which are isolated during the surgery. Scale bar=0.5cm. C-E) NIR 
Imaging of the collecting vessels following the surgery at days 7, 14, and 28 
respectively. Scale bar=0.5cm. F) Imaging of fluorescent lectin (wavelength 649) 
through the skin which is selectively up-taken by the lymphatic collecting vessels. The 
tissue within the yellow box is selectively isolated and sliced into 10μm cross-sections. 
Scale bar=0.5cm. G) One cross section of the isolated tissue located along the dotted 
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line of panel F. The red arrow indicates the location of the saphenous vein. The yellow 
box indicated the only vessel which was passively bound with lectin. Scale bar=100μm. 
H-K) Close-up of the DAPI, VEGFR-3, GFP positive tissue, and lectin stains, 
respectively, of the lectin stained collecting vessel. Scale bar=50μm. 
4.4.2 Use of biomaterial interventions to improve outcomes of ALND 
Generally, animals had a mild response to the surgery itself which is outlined in 
Figure 27. When grouping animals from all conditions, we see a statistically significant 
increase in fluorescent transport in response to surgery immediately following the surgery. 
There is a significant decrease in transport by day 28 compared to pre-surgical levels. This 
indicates that while the surgery did not induce swelling, it is impacting lymphatic function 
directly. The exact mechanism of this increase and eventual decrease in lymphatic function 




Figure 27: ALND Surgery: A) An anesthetized rat with an incision across the axilla. 
Muscle is loosely separated to gain access to the axillary lymph nodes (ALNs). B) 
Cartoon of the lymph nodes in the axillary pocket and their connection to upstream 
collecting vessels. C) An example of an intervention condition where a biomaterial 
(blue) is inserted after the nodes are removed. In some conditions a segment of the 
isolated lymph nodes was embedded into the biomaterial in-situ. D) Representative 
image of functional near infrared (NIR) imaging. The paw (out of the image at the 
top right) is injected with 15μL of 20kDa NIR dye which is selectively drained by the 
collecting vessel along the rat forelimb. Wrist diameter measurements were measured 
along the gold dashed line. A region of interest (ROI), such as the example shown with 
the gold dashed box, was selected along the forearm to measure dye transport. Scale 
bar=0.5cm. E) An example of average NIR fluorescent intensity in the ROI over time 
is shown. Contractions of the collecting vessel are seen as transient drops in average 
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intensity. F) Wrist diameter normalized to the initial diameter of the wrist for each 
rat at day 0.  G) Transport of NIR dye through the ROI prior to (day 0) and following 
the ALND surgery (transport is in arbitrary units). All animal conditions are 
combined for the measurements in panels F and G. Significance was determined via 
one-way ANOVA followed by Tukey’s multiple comparisons test.   
*: p<0.05, **: p<0.01 
When breaking animals down by the intervention condition, there is generally not 
a large response to the surgery or a discernible difference from each other in most 
conditions. There was no significant swelling produced at the wrist in the month following 
the initial surgery (Figure 28A). Swelling as a result of the oxazolone challenge to the 
forearm of animals was measured, starting at day 63, only on animals from the ALND and 
PEG/LN conditions. While there is a significant impact of oxazolone on the wrist diameter 
on day 66, swelling resolved by the following time point, despite an additional application 
of oxazolone being given on day 66. Furthermore, there was no difference in the response 
to oxazolone between the two conditions (Figure 28B). The only measurable impact of the 
surgery on lymphatic function is a slight increase in fluorescent transport on day 7 in the 
ALND condition (Figure 28C). Oxazolone did not significantly alter lymphatic function at 
timepoints 70 and 77 after its twice weekly application which began on day 63 (Figure 
28D). Implanting any biomaterial as an intervention did reduce the magnitude of the 
transient increase in fluorescent transport at day 7 compared to the ALND condition 




Figure 28: Impact of Interventions on Swelling Lymphatic Function (day 0 reflects 
presurgical measurements in all panels): A) Wrist diameter did not significantly 
change in any condition in the month following ALND surgeries. B) As a result of 
oxazolone application to the forearm, wrists did transiently swell in the ALND and 
PEG/LN conditions after 3 days but returned to pre-application levels by day 70 (One 
week after the initial application began). Extent of swelling was not different between 
the two conditions. C) Florescence transport in the month following ALND surgery 
revealed that in the absence of any intervention, transport significantly increases after 
one week before returning to initial levels. D) Oxazolone application did not 
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significantly impact transport. E) Wrist diameter did not significantly change when 
comparing the negative control, ALND, to the pooled results all biomaterial 
interventions. F) There is a significant increase in fluorescence transport in ALND 
negative control at day 7 compared to conditions where a biomaterial was embedded.  
Significance was determined via two-way ANOVA followed by Sidak’s multiple 
comparisons test.   
*: p<0.05, **: p<0.01, ***: p<0.001 
After the final functional NIR imaging, we collected tissue from animals after 
letting the animals rest for 30 minutes. We found that many animals had developed lymph 
node-like tissue in the axilla pocket where the ALNs where initially removed. This axillary, 
lymph draining, tissue (ALDT) formed in both the ALND and PEG/LN conditions. We 
removed this tissue, as well as the brachial lymph node (BLN), upstream of the ALNs, and 
assessed them for NIR dye as seen in Figure 29. In all conditions, both the ALDT and BLN 
have roughly equal fluorescent intensity signals, implying that both tissues were 
downstream of lymph formed at the injection site in the paw.  
 
Figure 29: NIR Dye Uptake of Lymph Nodes and Tissue at Day 98: A) Representative 
NIR images of the axillary lymph draining tissue (ALDT) and the brachial lymph 
node (BLN). Scale bar=0.2cm. B) Quantification of the fluorescent intensity of these 
tissues revealing no significant difference in dye uptake. Significance was determined 
via two-way ANOVA followed by Sidak’s multiple comparisons test.   
4.5 Discussion and Future Work 
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In this study we explore lymphatic damage and dysfunction animal models to attempt 
to determine if the degradable 10% PEG -2mM RGD gels can be used to transfer lymphatic 
tissue into a host. Our results expand on our understanding of lymphatic repair and 
regeneration mechanisms. After GFP-expressing lymphatic vessels were transferred to a 
host it appears that some cells migrated and become incorporated in a variety of the host 
vasculature within the wound site, most evident through the weak GFP fluorescence of the 
host saphenous vein. Tissue from the GFP expressing lymphatic vessels were shown to be 
functionally integrated into the host’s lymphatic vasculature via fluorescent lectin 
injection. The fact that this lectin coated vessel was over 50 microns and was 1-2inches 
downstream from the injection site would imply that it is a mature lymphatic collecting 
vessel but staining for LMC coverage remains to be done. Several GFP positive vessels, 
presumably smaller vessels that branched from the implanted segment, were found near 
the lectin stained collecting vessel but did not contain lectin. This likely indicates that these 
smaller vessels are initial lymphatics that do not drain from the injection site at the footpad.  
The scope of this aim was simply to show the feasibility of using PEG hydrogels to 
transplant lymphatic vessels segments but the innate repair response to the surgery alone 
was not been characterized. The individual contributions of the lymphatic vessel transplant 
or the PEG hydrogel alone remain to be studied as well. There has been work showing that 
application of collagen gel to the wound of a mouse tail lymphedema model improves 
lymphatic repair rate, reduces fibrosis, and alters immune cell recruitment199–201. 
Quantifications of these metrics in future studies will allow for a better understanding of 
how the PEG gel alone is impacting functional restoration of the injured lymphatic 
network. A future area of interest would be to determine if the transfer of tissue in this 
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lymphatic damage model impacts the abundance of host lymphatic vessels following 
surgery or improves metrics of lymphatic contractility. It has been shown that in a rat tail 
model of lymphedema injection of human LECs increased the number of rat lymphatic 
vessels in the wound site and reduced skin thickening and swelling from the surgery198.  
When using the axillary lymph node dissection animal model, we demonstrate the 
ability for lymphatics to maintain lymph flow and repair following surgery. The power of 
this study was low, limiting our ability to discern differences that may have existed. For 
example, comparisons of transport in the ALND animals between day 7 and 14 has a power 
of 0.6404. To explore some effects we combined conditions, as explained, in order to assess 
specific effects of surgery or intervention. Combining the results for all animals revealed 
some measurable impacts of the surgery across all conditions. Specifically, removal of the 
axillary lymph nodes induces a short-term increase in lymph transport measured at day 7 
but resolves by day 14. At the 28-day time point there is a reduction in fluorescence 
transport, but flow returned to presurgical levels by day 56 prior to oxazolone application 
(not shown). Implanting any biomaterial, with or without the lymph node segment, had a 
mitigating impact on this transient lymph transport spike seen in the ALND negative 
control. These results would seem to indicate that removal of the node reduces lymph flow 
resistance across the lymphatic network. This could lead to maladaptive remodelling of the 
collecting vessels to adjust to the elevated flow, explaining the reduction in flow at day 28. 
Future work isolating and characterizing the structure and force generation of the forelimb 




Delivering lymph node segments encapsulated in the PEG hydrogel did not alter 
lymphatic function of the forelimb lymphatics compared to implanting the PEG gel alone 
or using a type-1 collagen gel to encapsulate the node. It is important to note that in our 
model, ALN segments returned to the wound site were not vascularized which may have 
led to some of the ALN segments dying before revascularization could be achieved. We 
did find regenerated lymph node-like tissues in the axillary pocket that drained lymph in 
all experimental conditions. In our study, the wrists of animals undergoing ALND did not 
swell chronically similar to the results reported by Mendez et al, and future work could 
focus on how the regenerated lymph node-like tissue in our model contributed to mitigating 
lymphatic dysfunction202. It is unclear how or if our model varied from others and if other 
ALND models developed these lymph-node like tissues as well.  
Lymph node regeneration and enhancing the lymph node repair has been studied 
with some promising results.  As early as 1957, a study explored the lymphatic response 
after partial lymph node damage, partial lymph node resection, or full lymph node resection 
with results consistent with our findings203. This study looked at 4 different conditions of 
damaging or removing the single iliac lymph node. When the node was only mildly 
damaged, but still connected to the lymphatic network, the iliac lymph node repaired fairly 
robustly after 1-2 months. In conditions when lymph flow was disrupted through 
segmentation of the node or removal of the afferent or efferent vessels, 3-4 “lymphoid 
tissues” were found. As in our study, these lymphoid tissues contained dye from their 
injection upstream but lacked the clear structure of a mature lymph node. They also found 
that these regenerated nodes contained macrophages and drained lymph in the absence of 
the native, single iliac lymph node. Recent studies performing axillary lymph node 
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dissections have not reported the spontaneous formation of this type of lymphoid tissue, 
but it is unclear if these studies were designed in a manner to determine their 
presence60,202,204. Factors to promote lymph node regeneration have been explored recently, 
with it being demonstrated that implanting stromal cell–embedded biocompatible scaffolds 
can induce synthetic lymph node-like lymphoid tissue. These “artificial lymph nodes” can 
induce immune responses in addition to draining lymph205,206.The extent to which our 
implanted gels helped to facilitate the “ALDT” formation, or altered them compared to the 
non-intervention control is unclear and future work could explore how PEG hydrogels can 
be tuned to promote lymph node-like tissue formation and functionality.  
Perhaps the largest drawback of the lymphatic dysfunction models explored in this 
chapter are their inability to induce a chronic, negative, impact on lymphatic function or 
ensure LN segment engraftment. In the case of the ALND negative control, there were few 
measurable impacts on lymphatic function, and the few measured changes in lymphatic 
function were transient. The increased lymph transport resolved within a week and the 
oxazolone induced swelling resolved within a few days. A model with chronic lymphatic 
dysfunction and swelling would give us a better “baseline” to assess any beneficial effects 
of the biomaterial interventions. This could be accomplished by increasing the amount of 
lymphatic tissue resected or damaged, like what was done in a study that used diphtheria 
toxin injections in a transgenic animal model to locally ablate lymphatics207. Ultimately the 
goal would be to create a wound that slightly surpasses the ability of the lymphatics to 
naturally overcome. This is similar to studies in bone repair, where fractures are created 
that are slightly larger than what can heal naturally in order to assess the benefit of 
biomaterials and growth factors208.  Alternative metrics, such as measuring fluid content at 
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the wound site via bioimpedance or lymphatic vessel density in collected tissue have been 
shown to successfully determine lymphatic function in response to surgery models204. The 
transplanted LN segment was rarely found in the transplant conditions and we were not 
able to determine the extent to which they either became necrotic or became a part of the 
“ALDT”. Engraftment of the LN segments could be enhanced through either 
vascularization to the venous system or including VEGF-C, as has be done in similar 
studies60. 
In summary, our results contribute to our understanding of how lymphatics repair after 
surgical damage and how transplanted tissue and biomaterials influence this repair. We 
demonstrate that PEG hydrogels can facilitate transfer of lymphatic tissue and lay the 
ground work for an ALND model to determine the benefits of a PEG hydrogel. PEG gels 
tuned for lymphatic growth and regeneration could be used to minimize the amount of 
tissue needed for lymph node transfers in-vivo and improve their engraftment success rate. 
As it stands, the results we do gain from this ALND model further show how lymphatics 
transiently respond to lymph node removal, adjusting to changes in network resistance and 
loading. PEG hydrogels have the benefit of biocompatibility and modular design, without 
drawbacks involving sourcing, batch-to-batch variability, and immunogenicity that must 
be overcome with the clinical use of collagen gels209–211. Synthetic, maleimide cross-linked 
PEG hydrogels have greatly improved consistency in their biomechanical properties are 
easier to scale up for clinical use173. In the future I would propose repeating the ALND 
procedure but including resection of the brachial lymph node and nearby collateral vessels 




CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Conclusion 
We have presented multiple studies utilizing engineering tools to better understand 
how the biomechanical properties and loading of the extracellular matrix regulate 
lymphatic function. In chapter 2 we establish a healthy and disease lymphatic muscle cell 
line and explore how this initial phenotype of the LMC influence their response to 2D 
culture conditions.  For the first time the influence of cyclic stretch on lymphatic muscle 
cell function and protein synthesis is characterized. Through proteomic analysis we 
revealed that healthy, control, LMCs appeared to be more sensitive to stretch induced 
apoptosis, where remodelled LMCs were more resistant to apoptosis and upregulated 
pathways associated with oxidative stress, metabolic activity, and migration in response to 
cyclic strain. These results demonstrate the chronic nature of LMC remodelling after 
localized lymphatic damage and set the ground work for future studies in manipulating this 
phenotype. 
Modular poly(ethylene glycol) (PEG) based hydrogels were effectively used to 
explore the sensitivity of sprouting lymphangiogenesis to properties of the extracellular 
matrix. We show that sprouting is enhanced around a local optimal stiffness associated 
with the 10% PEG hydrogel stiffness of about 1.5kPa. Sprouting is extremely sensitive to 
the type of adhesive peptides available to the embedded tissue, with the adhesive peptide 
RGD significantly increasing the length and abundance of sprouts compared to the collagen 
based GFOGER peptide. Furthermore, we demonstrate that embedding collecting vessel 
segments in PEG gels allows for the study of the effects of clinically relevant 
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chemotherapeutics and drugs on lymphatic sprouting morphogenesis. Human lymphatic 
malformation tissue was successfully cultured within the 10% PEG-2mM hydrogels. This 
platform has been used to begin understanding the role of rapamycin on LM tissue and 
could act as a platform to screen a variety of microenvironment cues, drugs, and molecular 
regulators of lymphatic health and function.  
Finally, we present results on the application of PEG gels to enhance lymphatic 
transplantation and regeneration after damage to local lymphatic collecting vessel or lymph 
nodes. We show that PEG encapsulated lymphatic vessel segments can become 
incorporated into the host lymphatic network when transplanted and transport lymph from 
the interstitium by at least day 28. The impact of the axillary lymph node dissection rat 
model on the function of upstream lymphatic collecting vessel was explored and shown to 
lead to a transient increase in transport after one week but an eventual decrease in transport 
at day 28 day following the initial surgery. While the specific formulation of PEG hydrogel 
used did not outperform collagen gels at improving lymphatic function or engraftment, 
PEG hydrogels can be modified in a variety of ways to improve their impact for a specific 
application or function.  
5.2 Future Work 
While the work of this thesis demonstrates the feasibility of several platforms to 
study lymphatic function and regulation, many mechanistic and relevant biological 
questions remain unanswered. With regard to chapter 2, we demonstrate that our stretch 
waveform induces cellular responses consistent with vascular smooth muscle cell response 
to vascular damage and elevated loading. Stretch levels imposed were physiologically 
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relevant, but it remains unclear how slightly lower or higher amplitudes or frequencies 
would impact the response of LMCs. In addition, now that this platform is in place and the 
base response to a stretch waveform has been explored, future experiments could also look 
at how regulators found to be important in chapter 3 impact LMC response. Studies with 
VSMC would imply that pre-treatment with rapamycin, and culture with rapamycin during 
culture, may play a critical role in 2-D LMC phenotype in response to stretch. To create a 
more physiological phenotype of the LMCs, the impact of coculture and straining of LECs 
and LMCs could be explored to determine if LECs have a mitigating effect on LMC 
phenotypic changes.  
There are many directions that the work with PEG hydrogels to better understand 
lymphatic sprouting and function. Considering the literature indicating that 
lymphangiogenesis can exacerbate lymphedema in some conditions, it is critical to gain a 
better understanding of the phenotype of the sprouts produced in our PEG hydrogels. Our 
hydrogels were formulated to enhance the length and number of sprouts from the embedded 
tissue, but stains for junctional proteins or quantification of chemokine levels could give 
some indication of the functionality of these induced sprouts. Whether or not these sprouts 
contain lumens and if they can functionally transport fluid, proteins or cells has yet to be 
determined but is critical to determining how these results may translate to outcomes in-
vivo. Creating a gel that truly optimizes lymphatic healing in-vivo may require slightly 
different properties and embedded ligands. Along the same rationale, much more work also 
remains to be done to fully assess the impact of molecular regulators on sprout phenotype. 
Unanswered questions include how much these drugs alter sprout proliferation vs 
migration, junctional integrity, and pro- or anti-inflammatory signalling.  
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Culture of lymphatic malformation (LM) tissue presents a clinically relevant 
application of these gels. The degradable, 10% PEG – 2mM RGD hydrogel formulation 
was not optimized to for culture of lymphatic malformation tissue, and a systematic 
exploration of gel properties on these tissues may be needed to better recreate the behaviour 
of LM tissue in-vivo. Once sprouting within the gel is optimized several clinically relvant 
questions can be explored. For treatment it is important to know both how quickly 
rapamycin impacts LM growth and the optimal frequency of dosing. It is also unclear if 
patients can ever stop taking rapamycin or if LM growth would quickly resume after 
administration ends. This PEG gel platform allows for these questions to be explored in a 
somewhat high number and even on a patient specific manner. Finally alternative drugs 
and molecular regulators can be explored as alternatives to the non-specific administration 
of rapamycin. 
In the GFP study there is a significant amount of work to be done to determine the 
mechanism of the demonstrated repair and the contributions of each aspect of the presented 
work. While the PEG gel facilitated successful engraftment of the donated GFP lymphatic 
collecting vessel, several questions remain unanswered. It is unclear how the lymphatics 
of the hindlimb would naturally repair without intervention or if this lymphatic injury 
model would have induced swelling or lymphedema. Future work would need to determine 
if the PEG was necessary for the tissue to engraft, or if transferring vessel segments alone 
would naturally become incorporated into the local lymphatic network. Also, the impact of 
PEG injection alone, on both lymphatic repair and regulation of inflammatory cell 
recruitment to the wound site, remains to be studied. 
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A major shortcoming of the ALND in-vivo model was the inability to elicit a large 
chronic dysfunction of the lymphatics in the animal models as a negative control. Animals 
seemed to be able to naturally regenerate lymphatic function without intervention. 
Increased damage or resection of lymphatics near the node site is feasible and could be 
used to exacerbate the impact of the surgery on the function of upstream lymphatics. Efforts 
should be made to worsen lymphatic dysfunction as a result of lymph node dissection and 
to ensure lymph node engraftment. Tethering growth factors within the hydrogel, such as 
VEGF-C, or vascularizing the transplanted lymph node could improve the engraftment rate 
of the node, ensuring the tissue does not become necrotic. Culturing the lymph node 
segment in-vitro to form a lymphatic network around the node before implanting the gel 
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APOE,CFL1,HSD11B1,LGALS1,POMC,PTGS1,
SFTPA1,SOD1 8 
Free Radical Scavenging 
modification of reactive oxygen 
species 
6.39E-
07   1.953 CYCS,PTGS1,SOD1,TXN 4 
Molecular Transport transport of molecule 
4.21E-






Nucleic Acid Metabolism 
metabolism of nucleic acid 
component or derivative 
6.77E-
06   1.778 
ACACA,ACLY,APOE,ATP1B1,CAV1,CYCS,M
T-ATP6,PGD,POMC,PTGS1,RPSA,SOD1 12 
Nucleic Acid Metabolism, Small 
Molecule Biochemistry metabolism of nucleotide 0.00004   1.778 
APOE,ATP1B1,CAV1,CYCS,MT-
ATP6,PGD,POMC,PTGS1,RPSA,SOD1 10 
Nucleic Acid Metabolism, Small 
Molecule Biochemistry synthesis of nucleotide 
0.00027
7   1.778 
APOE,CAV1,CYCS,MT-
ATP6,POMC,PTGS1,RPSA,SOD1 8 
Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry concentration of lipid 
5.81E-




Lipid Metabolism, Small Molecule 
Biochemistry synthesis of lipid 
2.25E-





Lipid Metabolism, Small Molecule 
Biochemistry, Vitamin and Mineral 
Metabolism metabolism of terpenoid 
7.94E-
06   1.595 
ACLY,ALDH1A1,APOE,CAV1,HSD11B1,IGFB
P4,POMC,VIM,YWHAG 9 
Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry quantity of steroid 
8.85E-
05   1.507 
ALB,APOE,ATP1A1,CAV1,HSD11B1,IDH1,MI
F,POMC,PTGS1,TIMP1 10 
Lipid Metabolism, Small Molecule 
Biochemistry binding of lipid 
1.66E-
05   1.505 ANXA2,APOE,RPSA,SFN,SFTPA1 5 
Lipid Metabolism, Small Molecule 
Biochemistry synthesis of fatty acid 
1.94E-
07   1.474 
ACACA,ACLY,ALB,APOE,CAV1,MIF,PTGS1,S
ERPINC1,SOD1,TXN,VIM 11 
Inflammatory Response inflammation of body cavity 
2.12E-




Inflammatory Response, Organismal 








Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking 
cell movement of antigen 
presenting cells 
4.66E-
05   -1.55 
APOE,CAV1,ITGB1,LGALS1,MIF,MYLK,PF4,S
FTPA1,TIMP1 9 
Neurological Disease Neurodegeneration 
0.00011
4   -1.554 
APOE,ATP1B1,CAV1,CTSB,CTSD,GAPDH,SO
D1,VIM 8 
Cell-To-Cell Signaling and 
Interaction, Hematological System 
Development and Function binding of leukocytes 
0.00012
1   -1.58 APOE,DCN,ITGB1,PF4,POMC,SFTPA1 6 
Hematological System Development 
and Function, Tissue Development accumulation of myeloid cells 
1.19E-
05   -1.586 APOE,CRYAB,ITGB1,MIF,POMC,SOD1,TIMP1 7 
Organismal Development growth of vessel 
6.72E-
05   -1.606 APOE,CTSB,HSD11B1,ITGB1,LGALS1,TIMP1 6 
Cellular Movement migration of cells 
3.69E-







Cancer, Organismal Injury and 
Abnormalities tumorigenesis of tissue 
0.00025














Endocrine System Disorders, 
Metabolic Disease insulin resistance 0.00002   -1.644 
ACACA,AHSG,APOE,CAV1,HSD11B1,MIF,PO
MC,PTGS1,SOD1 9 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking 
cellular infiltration by 
mononuclear leukocytes 
1.12E-
06   -1.658 
APOE,BGN,ITGB1,LGALS1,MIF,MYLK,PF4,TI
MP1 8 
Cellular Development, Connective 
Tissue Development and Function, 
Tissue Development 
differentiation of connective 
tissue 
0.00036
2   -1.671 
APOE,BGN,CAST,HSD11B1,ITGB1,MIF,PRKA
CA,SFXN1,SOD1,TIMP1,VIM,YWHAZ 12 
Protein Synthesis quantity of IL-6 in blood 
0.00033
1   -1.732 APOE,CAV1,POMC,SOD1 4 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking cell movement of leukocytes 
1.28E-




Cell Death and Survival 
apoptosis of prostate cancer cell 
lines 
0.00014
1   -1.758 ACACA,CAV1,IGFBP4,ITGB1,LGALS1,SOD1 6 
Cellular Movement, Immune Cell 
Trafficking leukocyte migration 
2.03E-





Cellular Movement cell movement 
5.11E-







Hematological System Development 
and Function, Immune Cell 
Trafficking, Inflammatory Response, 
Tissue Development accumulation of leukocytes 
2.65E-
05   -1.843 
APOE,BGN,ITGB1,MIF,POMC,SERPINC1,SOD
1,TIMP1 8 
Cellular Movement chemotaxis 
0.00036






Organismal Survival morbidity or mortality 
1.68E-







Cell Death and Survival, Organismal 
Injury and Abnormalities necrosis of epithelial tissue 
4.54E-




Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking, 
Inflammatory Response migration of neutrophils 
9.27E-
05   -1.927 ALB,ITGB1,MYLK,SERPINC1,TXN 5 
Cellular Movement, Skeletal and 
Muscular System Development and 
Function migration of smooth muscle cells 
0.00038
5   -1.932 APOE,IGFBP4,ITGB1,TIMP1,TXN 5 
Cell Death and Survival cell death of leukemia cell lines 
2.21E-
06   -1.956 
CAV1,CTSB,CTSD,CYCS,FTH1,GAPDH,ITGB1
,LGALS1,PRKACA,YWHAG 10 
Hematological System Development 
and Function, Immune Cell 
Trafficking, Inflammatory Response, 
Tissue Development accumulation of phagocytes 
0.00036
5   -1.959 APOE,ITGB1,MIF,SOD1,TIMP1 5 
Cardiovascular Disease Infarction 
3.01E-
05   -1.992 
APOE,ATP1A1,CAV1,MIF,PTGS1,SERPINC1,S
OD1,TIMP1,TXN 9 
Protein Synthesis quantity of TNF in blood 
0.00024
2 Decreased -2 APOE,CAV1,MIF,SOD1 4 
Cell Morphology, Cellular Movement cell spreading of blood cells 
0.00031
7 Decreased -2 ALB,CAST,ITGB1,LGALS1 4 
Cell Death and Survival 
necrosis of prostate cancer cell 
lines 
3.67E-
05 Decreased -2.022 
ACACA,CAV1,IGFBP4,ITGB1,LGALS1,SOD1,
TXN 7 











Cardiovascular System Development 
and Function, Tissue Morphology permeability of blood vessel 2.8E-06 Decreased -2.19 APOE,CAV1,MIF,MYLK,SERPINC1,TIMP1 6 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking 
cell movement of mononuclear 
leukocytes 
0.00008
5 Decreased -2.199 
ACTB,ANXA2,APOE,BGN,ITGB1,LGALS1,MI
F,MYLK,PF4,TIMP1 10 
Organismal Injury and Abnormalities Organ Degeneration 
1.46E-
05 Decreased -2.212 
APOE,ASPM,ATP1B1,CAV1,CTSB,CTSD,GAP
DH,PTGS1,SERPINC1,SOD1,TXN,VIM 12 
Cellular Function and Maintenance ion homeostasis of cells 
0.00014
3 Decreased -2.219 
ALB,ANXA2,APOE,ATP1A1,ATP1B1,CAV1,FT
L,ITGB1,PF4,PYGM,SOD1 11 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking, 
Inflammatory Response cell movement of macrophages 
0.00025
6 Decreased -2.278 APOE,CAV1,ITGB1,MIF,MYLK,PF4,SFTPA1 7 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking, 
Inflammatory Response cell movement of phagocytes 
9.27E-




Cardiovascular System Development 
and Function, Hematological System 
Development and Function blood pressure 
1.46E-






Cellular Development differentiation of cells 
2.94E-






Neurological Disease, Organismal 
Injury and Abnormalities, 
Psychological Disorders Dementia 
3.47E-






Metabolic Disease, Neurological 
Disease, Organismal Injury and 
Abnormalities, Psychological 
Disorders Alzheimer disease 
1.25E-






Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities psoriasis 
2.89E-




Cancer, Organismal Injury and 
Abnormalities, Reproductive System 









Hereditary Disorder, Organismal 
Injury and Abnormalities autosomal dominant disease 
4.88E-






Endocrine System Disorders, 
Organismal Injury and Abnormalities thyroid nodule 
9.83E-
09     AHSG,ALDH1A1,CTSB,EEF1D,FTL,MT-ND5 6 
Neurological Disease, Organismal 
Injury and Abnormalities, 
Psychological Disorders disorder of basal ganglia 
1.27E-




Neurological Disease, Skeletal and 
Muscular Disorders neuromuscular disease 
2.46E-




Cancer, Hematological Disease, 
Organismal Injury and Abnormalities lymphohematopoietic neoplasia 
5.48E-








Neurological Disease progressive motor neuropathy 
7.14E-




Cancer, Organismal Injury and 
Abnormalities benign neoplasia 
7.67E-





Cancer, Hematological Disease, 
Organismal Injury and Abnormalities lymphohematopoietic cancer 
1.01E-








Cardiovascular Disease, Organismal 
Injury and Abnormalities bleeding of blood vessel 1.2E-07     APOE,BGN,CNN1,POMC 4 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease breast cancer 
1.29E-















Connective Tissue Disorders, 
Immunological Disease, Inflammatory 
Disease, Inflammatory Response, 
Organismal Injury and Abnormalities, 
Skeletal and Muscular Disorders juvenile rheumatoid arthritis 
3.08E-
07     
ACLY,ALB,APOE,ATP1B1,LGALS1,MIF,PTGS
1,RPSA,TXN 9 
Connective Tissue Disorders, 
Immunological Disease, Inflammatory 
Disease, Inflammatory Response, 
Organismal Injury and Abnormalities, 
Skeletal and Muscular Disorders rheumatoid arthritis 
3.12E-




Endocrine System Disorders, 
Organismal Injury and Abnormalities benign thyroid nodule 
3.14E-
07     AHSG,ALDH1A1,CTSB,EEF1D,FTL 5 
Cellular Function and Maintenance, 
Small Molecule Biochemistry homeostasis of metal ion 3.9E-07     
APOE,ATP1A1,ATP1B1,CAV1,FTL,ITGB1,PF4,
PYGM,SOD1 9 
Infectious Diseases attachment of virus 
3.95E-
07     ANXA2,APOE,FTL,LGALS1 4 
Cancer, Hematological Disease, 
Organismal Injury and Abnormalities hematological neoplasia 
6.04E-







Cancer, Organismal Injury and 




Cardiovascular System Development 
and Function, Organ Morphology contraction of heart 
9.67E-
07     
ATP1A1,ATP1B1,CALM1 (includes 
others),CRYAB,ITGB1,MYLK,PRKACA,SOD1 8 
Organismal Injury and Abnormalities, 
Respiratory Disease acute lung injury 
9.94E-
07     AHSG,ALB,CAV1,GAPDH,MIF,PTGS1,SFTPA1 7 
Cancer, Hematological Disease, 
Organismal Injury and Abnormalities hematologic cancer 
1.05E-







Cellular Function and Maintenance, 
Small Molecule Biochemistry homeostasis of divalent cations 
1.16E-
06     
APOE,ATP1B1,CAV1,FTL,ITGB1,PF4,PYGM,S
OD1 8 
Hematological Disease blood protein disorder 
1.27E-
06     
ALB,ANXA2,ATP1B1,CAV1,CRYAB,PF4,PTG
S1,SERPINC1,TIMP1,VIM,YWHAE,YWHAZ 12 
Cellular Assembly and Organization, 
Cellular Compromise 
formation of cellular inclusion 
bodies 
1.39E-
06     APOE,CAST,CRYAB,CTSB,FTL,SOD1 6 
Carbohydrate Metabolism synthesis of monosaccharide 
1.48E-
06     ALDH1A1,APOE,GAPDH,MIF,PGD,POMC 6 
Lipid Metabolism, Small Molecule 
Biochemistry regulation of cholesterol 
1.68E-
06     APOE,CAV1,POMC 3 
Neurological Disease, Organismal 






Cancer, Organismal Injury and 
Abnormalities Lymphoid Cancer and Tumors 
1.81E-







Cancer, Hematological Disease, 
Immunological Disease, Organismal 
Injury and Abnormalities plasma cell dyscrasia 
1.98E-
06     
ANXA2,ATP1B1,CAV1,CRYAB,PF4,PTGS1,SE
RPINC1,TIMP1,VIM,YWHAE,YWHAZ 11 
Cell Morphology morphology of cells 
2.21E-






Cell Signaling, Cellular Function and 
Maintenance, Small Molecule 
Biochemistry, Vitamin and Mineral 
Metabolism homeostasis of Ca2+ 
2.49E-
06     APOE,ATP1B1,CAV1,ITGB1,PF4,PYGM,SOD1 7 
Metabolic Disease, Neurological 
Disease beta amyloidosis 
2.68E-
06     APOE,CAST,VIM 3 
Connective Tissue Development and 
Function, Skeletal and Muscular 
System Development and Function, 
Tissue Morphology quantity of osteoprogenitor cells 
2.68E-
06     BGN,DCN,SOD1 3 
Neurological Disease, Organismal 
Injury and Abnormalities, 
Psychological Disorders, Skeletal and 
Muscular Disorders Parkinson's disease 
3.78E-
06     
ALB,ANXA2,APOE,CRYAB,FTH1,FTL,MT-
ND5,SOD1,VIM 9 
Developmental Disorder, Hereditary 
Disorder, Ophthalmic Disease, 
Organismal Injury and Abnormalities familial congenital cataract 
3.81E-
06     CAV1,CRYAB,FTL,VIM 4 
Carbohydrate Metabolism catabolism of polysaccharide 
4.19E-
06     APOE,CTSB,PYGB,PYGL,PYGM 5 
Immunological Disease systemic autoimmune syndrome 
5.33E-




Cancer, Gastrointestinal Disease, 
Hepatic System Disease, Organismal 
Injury and Abnormalities hepatocellular carcinoma 
5.65E-




Skeletal and Muscular System 
Development and Function morphology of muscle 
7.22E-
06     
APOE,BGN,CAST,CAV1,DCN,HSD11B1,IGFBP
4,ITGB1,SERPINC1,SOD1,YWHAE 11 
Cellular Function and Maintenance uptake of bacteria 
7.33E-
06     CAV1,ITGB1,RPSA,SFTPA1 4 
Developmental Disorder, Hereditary 
Disorder, Metabolic Disease, 
Neurological Disease, Ophthalmic 
Disease, Organismal Injury and 
Abnormalities, Skeletal and Muscular 
Disorders Leber optic atrophy 
7.82E-
06     MT-ATP6,MT-ND3,MT-ND5 3 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease 
tumorigenesis of reproductive 
tract 
8.14E-









Cardiovascular Disease peripheral vascular disease 
8.24E-






Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease female genital neoplasm 
8.32E-









Cancer, Organismal Injury and 
Abnormalities urogenital cancer 
8.78E-









Organ Morphology abnormal morphology of gland 
1.03E-
05     
ALDH1A1,APOE,CAV1,CTSB,HSD11B1,IGFBP
4,POMC,RPSA,SOD1 9 
Cardiovascular Disease, Neurological 
Disease 
ischemia of central nervous 
system 
1.03E-
05     ALB,CAV1,PLP2,PTGS1,PYGL,SERPINC1 6 
Lipid Metabolism, Small Molecule 
Biochemistry regulation of lipid 
1.04E-
05     APOE,CAV1,POMC,PTGS1 4 
Ophthalmic Disease, Organismal 
Injury and Abnormalities damage of retina 
1.04E-
05     CRYAB,SOD1,TXN 3 
Molecular Transport, Protein 
Trafficking excretion of protein 
1.04E-
05     CNN1,MIF,PRKACA 3 
Energy Production, Lipid Metabolism, 
Small Molecule Biochemistry 
oxidation of polyunsaturated 
fatty acids 
1.04E-
05     APOE,CYCS,PTGS1 3 
Organ Morphology morphology of gland 
1.07E-
05     
ALDH1A1,APOE,CAV1,CTSB,HSD11B1,IGFBP
4,ITGB1,POMC,RPSA,SOD1 10 
Cancer, Hematological Disease, 
Organismal Injury and Abnormalities lymphoid cancer 
1.21E-







neurite outgrowth stage of dorsal 
root ganglion cells 
1.35E-
05     ITGB1,VIM 2 
Cellular Development, Cellular 
Growth and Proliferation 
re-entry into growth of leukemia 
cell lines 
1.35E-
05     FTH1,FTL 2 
Cardiovascular System Development 
and Function, Organismal 
Development, Tissue Morphology area of blood vessel 
1.35E-
05     APOE,PF4,VIM 3 
Free Radical Scavenging 
modification of hydrogen 
peroxide 
1.35E-
05     PTGS1,SOD1,TXN 3 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease tumorigenesis of genital organ 
1.38E-









Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease genital tumor 
0.00001









Nervous System Development and 
Function morphology of nervous system 
1.51E-







Cancer, Organismal Injury and 
Abnormalities, Respiratory Disease carcinoma in lung 
0.00001




Skeletal and Muscular System 
Development and Function relaxation of muscle 
1.66E-
05     APOE,ATP1A1,ATP1B1,MYLK,SOD1 5 
Cardiovascular System Development 
and Function contractility of artery 
1.71E-
05     CAV1,IGFBP4,SOD1 3 
Hereditary Disorder, Neurological 
Disease, Organismal Injury and 
Abnormalities, Psychological 
Disorders familial dementia 
1.73E-
05     APOE,BGN,CTSD,SOD1 4 
Lipid Metabolism, Molecular 
Transport, Nucleic Acid Metabolism, 




05     ACACA,ACLY,IDH1 3 
Psychological Disorders schizophrenia spectrum disorder 
2.14E-
05     
ATP1A1,CAV1,CTSB,HPCAL1,LGALS1,MT-
ATP6,MT-CO2,POMC,PTGS1,RPL10,YWHAE 11 
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities chronic psoriasis 
2.44E-
05     APOE,ATP1B1,CNN1,CTSB,H2AFZ,PGD 6 
Cellular Movement 
invasion of pancreatic cancer cell 
lines 
2.49E-
05     CAV1,CTSD,SFN,TIMP1 4 
Developmental Disorder, Organismal 
Injury and Abnormalities dystrophy 
2.65E-
05     
ACLY,APOE,BGN,CAST,CFL1,CYCS,ITGB1,V
IM 8 
Inflammatory Disease, Organismal 
Injury and Abnormalities, Respiratory 
Disease 
acute respiratory distress 
syndrome 
2.69E-
05     ALB,GAPDH,MIF,PTGS1,SFTPA1 5 
Organismal Injury and Abnormalities, 
Tissue Morphology size of lesion 
2.85E-
05     
APOE,CAV1,CRYAB,CTSB,MIF,PF4,SOD1,TI
MP1,TXN 9 
Cardiovascular Disease, Neurological 
Disease, Organismal Injury and 
Abnormalities cerebrovascular dysfunction 
3.02E-
05     
ALB,APOE,ATP1A1,PLP2,PTGS1,PYGL,SERPI
NC1,VIM 8 
Cancer, Organismal Injury and 
Abnormalities papillary carcinoma 
3.08E-




Hematological Disease, Organismal 
Injury and Abnormalities venous thromboembolism 
3.17E-
05     ALB,PTGS1,SERPINC1 3 
Hereditary Disorder, Neurological 
Disease, Organismal Injury and 
Abnormalities hereditary neuropathy 
0.00003
4     
APOE,BGN,CAV1,MT-ATP6,MT-ND3,MT-
ND5,SOD1 7 
Cell-To-Cell Signaling and 
Interaction, Nervous System 
Development and Function activation of astrocytes 
3.48E-
05     ALB,MIF,SOD1,VIM 4 
Organismal Development morphology of body cavity 
3.65E-





Connective Tissue Disorders, 
Immunological Disease, Inflammatory 
Disease, Inflammatory Response, 
Organismal Injury and Abnormalities, 




05     APOE,LGALS1,PTGS1,RPSA,TXN 5 
Cell Death and Survival 
apoptosis of bone marrow 
stromal cells 
4.03E-
05     BGN,DCN 2 
Cell-To-Cell Signaling and 
Interaction, Connective Tissue 
Development and Function 
binding of bone marrow stromal 
cells 
4.03E-




Neurological Disease, Organismal 
Injury and Abnormalities leukoencephalopathy 
4.36E-
05     APOE,CAV1,MT-ATP6,MT-ND3,MT-ND5 5 
Lipid Metabolism, Small Molecule 
Biochemistry stimulation of prostaglandin 
0.00004
5     ANXA2,MIF,PTGS1 3 
Organ Morphology morphology of endocrine gland 
0.00004
6     
APOE,CAV1,CTSB,HSD11B1,IGFBP4,POMC,R
PSA 7 
Hereditary Disorder, Organismal 
Injury and Abnormalities, Skeletal and 
Muscular Disorders hereditary myopathy 
5.07E-
05     
ACLY,BGN,CAST,CFL1,CRYAB,CYCS,ITGB1,
MT-ATP6,MT-ND3,MT-ND5 10 
Metabolic Disease abnormal metabolism 
5.27E-
05     APOE,HSD11B1,IGFBP4,ITGB6,POMC,PTGS1 6 
Molecular Transport import of metal ion 
5.28E-
05     ATP1A1,ATP1B1,CFL1 3 
Nervous System Development and 
Function, Organ Morphology, 
Organismal Development morphology of cerebral cortex 
5.32E-
05     
APOE,ASPM,CAV1,CTSB,HSD11B1,VIM,YWH
AE 7 
Cardiovascular System Development 
and Function, Organ Morphology, 
Skeletal and Muscular System 
Development and Function contraction of cardiac muscle 
5.45E-
05     
ATP1A1,ATP1B1,CALM1 (includes 
others),MYLK,PRKACA 5 
Skeletal and Muscular System 
Development and Function mass of muscle 
5.45E-
05     CAST,HSD11B1,IGFBP4,ITGB1,SOD1 5 
Respiratory System Development and 
Function morphology of respiratory tract 
5.45E-
05     
ALDH1A1,APOE,CAV1,HSD11B1,ITGB6,LGA
LS1,SFTPA1 7 
Cancer, Gastrointestinal Disease, 
Hepatic System Disease, Organismal 
Injury and Abnormalities bile duct adenocarcinoma 
5.94E-
05     ALB,ANXA2,IDH1,SERPINC1,VIM 5 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease female genital tract cancer 
6.08E-









Endocrine System Development and 
Function, Lipid Metabolism, 
Molecular Transport, Small Molecule 
Biochemistry secretion of corticosterone 
6.14E-
05     APOE,HSD11B1,POMC 3 
Drug Metabolism, Lipid Metabolism, 
Small Molecule Biochemistry synthesis of epoprostenol 
6.14E-
05     PTGS1,SERPINC1,SOD1 3 
Cardiovascular Disease, Organismal 
Injury and Abnormalities arrhythmia 
6.43E-
05     
ATP1A1,ATP1B1,CALM1 (includes 
others),PTGS1,SERPINC1,TIMP1,TXN 7 
Respiratory System Development and 
Function compliance of lung 
7.09E-
05     APOE,CAV1,SFTPA1 3 
Lipid Metabolism, Small Molecule 
Biochemistry induction of lipid 
7.09E-
05     LGALS1,MIF,PTGS1 3 
Neurological Disease, Psychological 
Disorders Schizophrenia 
7.42E-
05     
ATP1A1,CAV1,CTSB,HPCAL1,LGALS1,MT-
ATP6,MT-CO2,POMC,PTGS1,YWHAE 10 
Connective Tissue Disorders, 
Organismal Injury and Abnormalities, 
Tissue Morphology abnormal morphology of fat pad 
7.65E-




Cancer, Organismal Injury and 
Abnormalities pelvic cancer 
7.83E-









Cell Morphology, Endocrine System 
Development and Function, Endocrine 
System Disorders, Organ Morphology, 
Organismal Development, Organismal 
Injury and Abnormalities 
abnormal morphology of thyroid 
follicle cells 
8.04E-
05     CAV1,CTSB 2 
Cardiovascular System Development 
and Function, Organismal 
Development, Tissue Morphology area of carotid artery 
8.04E-
05     APOE,VIM 2 
Drug Metabolism, Endocrine System 
Development and Function, Lipid 
Metabolism, Small Molecule 
Biochemistry conversion of hydrocortisone 
8.04E-
05     HSD11B1,POMC 2 
Free Radical Scavenging modification of superoxide 
8.04E-
05     CYCS,SOD1 2 
Energy Production, Lipid Metabolism, 
Small Molecule Biochemistry oxidation of arachidonic acid 
8.04E-
05     APOE,PTGS1 2 
Cell Death and Survival, Organismal 
Injury and Abnormalities, Renal and 
Urological Disease apoptosis of mesangial cells 
8.13E-
05     APOE,BGN,ITGB1 3 
Developmental Disorder, Hereditary 
Disorder, Metabolic Disease, 
Neurological Disease, Organismal 
Injury and Abnormalities, 
Psychological Disorders familial Alzheimer disease 
8.13E-
05     APOE,BGN,CTSD 3 
Lipid Metabolism, Small Molecule 
Biochemistry redistribution of lipid 
8.13E-
05     APOE,ATP1A1,LGALS1 3 
Cancer, Organismal Injury and 
Abnormalities breast or ovarian carcinoma 
8.61E-






Nervous System Development and 
Function, Neurological Disease, Organ 
Morphology, Organismal 
Development, Organismal Injury and 
Abnormalities 
abnormal morphology of 
hippocampus 
8.92E-
05     APOE,CAV1,CTSB,HSD11B1,YWHAE 5 
Ophthalmic Disease, Organismal 
Injury and Abnormalities cataract disease 
8.92E-
05     ALDH1A1,CAV1,CRYAB,FTL,VIM 5 
Organismal Injury and Abnormalities, 
Tissue Morphology volume of lesion 
8.92E-
05     CAV1,CRYAB,MIF,SOD1,TIMP1 5 
Cell Cycle interphase of blood cells 
9.23E-
05     DCN,ITGB1,LGALS1,TIMP1 4 
Carbohydrate Metabolism catabolism of glycogen 
9.27E-
05     PYGB,PYGL,PYGM 3 
Free Radical Scavenging, Small 
Molecule Biochemistry 
degradation of hydrogen 
peroxide 
9.27E-
05     PTGS1,SOD1,TXN 3 
Endocrine System Development and 
Function, Lipid Metabolism, Small 
Molecule Biochemistry, Vitamin and 
Mineral Metabolism synthesis of glucocorticoid 
9.27E-
05     ATP1A1,HSD11B1,POMC 3 
Cardiovascular Disease aneurysm 
9.27E-




Cell Morphology, Cell-To-Cell 
Signaling and Interaction 
morphology of intercellular 
junctions 
9.27E-
05     APOE,CAV1,LGALS1,STX1B,YWHAG 5 
Cancer, Immunological Disease, 
Organismal Injury and Abnormalities neoplasia of lymphoid organ 
9.74E-
05     AHSG,APOE,DCN,ITGB1,PTGS1,VIM 6 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease genital tract cancer 
0.00010









Nervous System Development and 
Function, Neurological Disease 
abnormal morphology of 
nervous system 
0.00010




Organ Morphology morphology of skin 
0.00010
6     
APOE,BGN,CAST,CTSB,DCN,ITGB1,ITGB6,P
OMC 8 
Embryonic Development, Organ 
Development, Organ Morphology, 
Organismal Development, Organismal 
Injury and Abnormalities, Respiratory 
Disease, Respiratory System 
Development and Function, Tissue 
Development 
abnormal morphology of 
pulmonary alveolus 
0.00010
8     APOE,CAV1,HSD11B1,ITGB6,SFTPA1 5 
Inflammatory Response, Neurological 
Disease neuroinflammation 
0.00011
8     MIF,SOD1,VIM 3 
Cancer, Hematological Disease, 
Immunological Disease, Organismal 
Injury and Abnormalities multiple myeloma 
0.00011
9     
CRYAB,PF4,PTGS1,SERPINC1,TIMP1,VIM,Y
WHAZ 7 
Developmental Disorder, Hereditary 
Disorder, Organismal Injury and 
Abnormalities, Skeletal and Muscular 
Disorders Duchenne muscular dystrophy 0.00012     ACLY,BGN,CAST,CFL1,CYCS 5 
Neurological Disease neurological signs 
0.00012
4     
ACTB,APOE,ATP1B1,CAV1,COX7A2,CRYAB,
CYCS,GAPDH,RPSA,SOD1,TXN,YWHAZ 12 
Cardiovascular Disease, Neurological 
Disease, Organismal Injury and 
Abnormalities ischemia of brain 
0.00012
5     ALB,PLP2,PTGS1,PYGL,SERPINC1 5 
Cancer, Organismal Injury and 
Abnormalities, Respiratory Disease non-small cell lung cancer 
0.00012




Cell-To-Cell Signaling and 
Interaction, Embryonic Development binding of embryonic cell lines 
0.00013
3     ANXA2,CAV1,ITGB1 3 
Cellular Function and Maintenance 
engulfment of mononuclear 
leukocytes 
0.00013
3     APOE,PF4,SFTPA1 3 
Lipid Metabolism, Small Molecule 
Biochemistry mobilization of lipid 
0.00013
3     CAV1,LGALS1,POMC 3 
Hematological System Development 
and Function, Immune Cell 





4     APOE,SOD1 2 
Cardiovascular Disease, 
Hematological Disease, Organismal 
Injury and Abnormalities atherothrombosis 
0.00013
4     APOE,PTGS1 2 
Cell-To-Cell Signaling and Interaction 
attachment of melanoma cell 
lines 
0.00013
4     ITGB1,RPSA 2 
Lipid Metabolism, Molecular 
Transport, Nucleic Acid Metabolism, 








Lipid Metabolism, Nucleic Acid 
Metabolism, Small Molecule 
Biochemistry 
conversion of acetyl-coenzyme 
A 
0.00013
4     ACACA,ACLY 2 
Cellular Compromise degradation of autophagosomes 
0.00013
4     CTSB,CTSD 2 
Tissue Development development of stroma 
0.00013
4     ALDH1A1,CAV1 2 
Lipid Metabolism, Small Molecule 
Biochemistry incorporation of arachidonic acid 
0.00013
4     ACLY,CAV1 2 
Cell-To-Cell Signaling and 
Interaction, Cellular Function and 
Maintenance, Hematological System 
Development and Function, 
Inflammatory Response phagocytosis of monocytes 
0.00013
4     PF4,SFTPA1 2 
Lipid Metabolism, Small Molecule 
Biochemistry stimulation of phospholipid 
0.00013
4     LGALS1,POMC 2 
Neurological Disease, Skeletal and 
Muscular Disorders tremor of limb 
0.00013
4     SOD1,TIMP1 2 
Cancer, Endocrine System Disorders, 
Organismal Injury and Abnormalities, 
Reproductive System Disease Ovarian Cancer and Tumors 
0.00013






abnormality of peripheral 
ganglia 
0.00014
4     APOE,LGALS1,MIF,PRKACA,SOD1 5 
Lipid Metabolism, Small Molecule 
Biochemistry, Vitamin and Mineral 
Metabolism synthesis of steroid hormone 
0.00014
6     ATP1A1,HSD11B1,POMC,VIM 4 
Cancer, Organismal Injury and 
Abnormalities, Reproductive System 
Disease 
female genital tract serous 
carcinoma 
0.00014
6     
ALDH1A1,ANXA2,APOE,CNN1,HSD11B1,IGF
BP4,MYLK,PDXK,PTGS1 9 
Hematological System Development 
and Function, Organismal Functions coagulation of blood 
0.00014
8     ANXA2,APOE,CAV1,PF4,PTGS1,SERPINC1 6 
Immunological Disease allergy 
0.00015
3     
ACTB,ALB,BGN,CFL1,GAPDH,LGALS1,POM
C,PTGS1,TIMP1 9 
Nervous System Development and 
Function, Neurological Disease, Organ 
Morphology, Organismal 
Development, Organismal Injury and 
Abnormalities 
abnormal morphology of 
cerebral cortex 0.00016     APOE,ASPM,CAV1,CTSB,HSD11B1,YWHAE 6 
Cancer, Endocrine System Disorders, 
Organismal Injury and Abnormalities 
benign neoplasm of endocrine 
gland 0.00016     ANXA2,ATP1A1,CTSB,DCN,POMC,PRKACA 6 
Cancer, Organismal Injury and 
Abnormalities papillary adenocarcinoma 
0.00016
1     
ATP1B1,HSD11B1,IGFBP4,MT-ND3,MT-
ND5,TIMP1,VIM 7 
Embryonic Development, Organ 
Development, Organismal 
Development, Reproductive System 
Development and Function, Tissue 
Development lactation 
0.00016
3     CAV1,CSN2,CSN3,ITGB1 4 
Hematological Disease, Organismal 
Injury and Abnormalities thrombocytosis 
0.00016
3     ATP1B1,IDH1,PF4,PTGS1 4 
Cell-To-Cell Signaling and 
Interaction, Hair and Skin 
Development and Function binding of epithelial cell lines 
0.00016
5     ANXA2,CAV1,ITGB1 3 
Cancer, Gastrointestinal Disease, 
Organismal Injury and Abnormalities oral cancer 
0.00019






Cellular Movement scattering of cells 
0.00019
9     ANXA2,CFL1,ITGB1,TIMP1 4 
Cardiovascular Disease, Connective 
Tissue Disorders, Hematological 
Disease, Organismal Injury and 
Abnormalities 
heparin-induced 
thrombocytopenia 0.0002     PTGS1,SERPINC1 2 
Cell Morphology, Nervous System 
Development and Function, 
Neurological Disease, Tissue 
Morphology loss of motor axons 0.0002     CAST,SOD1 2 
Organismal Injury and Abnormalities, 
Reproductive System Disease placental insufficiency 0.0002     PTGS1,SERPINC1 2 
Molecular Transport, Small Molecule 
Biochemistry quantity of melanin 0.0002     MIF,POMC 2 
Drug Metabolism, Lipid Metabolism, 
Molecular Transport, Small Molecule 
Biochemistry release of epoprostenol 0.0002     PTGS1,SERPINC1 2 
Cancer, Organismal Injury and 
Abnormalities, Tissue Morphology, 
Tumor Morphology size of tumor 
0.00020
1     CAV1,CTSB,MIF,PF4,TIMP1 5 
Embryonic Development, Organ 
Development, Organ Morphology, 
Organismal Development, 
Reproductive System Development 
and Function, Tissue Development 
morphogenesis of mammary 
gland 
0.00020
2     CAV1,ITGB1,TIMP1 3 
Cardiovascular Disease, Organismal 
Injury and Abnormalities aortic aneurysm 
0.00020
9     APOE,FTL,MYLK,TIMP1 4 
Organismal Injury and Abnormalities calcinosis 
0.00020
9     AHSG,APOE,PTGS1,TIMP1 4 
Nervous System Development and 
Function thermal nociception 
0.00020
9     APOE,LGALS1,POMC,PTGS1 4 
Cardiovascular Disease, Organismal 
Injury and Abnormalities, Skeletal and 
Muscular Disorders atrial fibrillation 
0.00021
4     ATP1A1,ATP1B1,PTGS1,SERPINC1,TIMP1 5 
Cancer, Organismal Injury and 
Abnormalities 
malignant neoplasm of 
aerodigestive tract 
0.00021
4     
ALDOB,BGN,CAV1,CNN1,CRYAB,DCN,FTH1,
LGALS1,PTGS1,RPL10,SFN,TIMP1,YWHAB 13 
Dermatological Diseases and 
Conditions, Inflammatory Disease, 
Inflammatory Response, Organismal 
Injury and Abnormalities Dermatitis 0.00022     
APOE,ATP1A1,BGN,CFL1,LGALS1,POMC,PT
GS1,SFN,TIMP1 9 
Hereditary Disorder, Metabolic 
Disease, Neurological Disease, 
Organismal Injury and Abnormalities, 
Skeletal and Muscular Disorders Leigh syndrome 
0.00022
2     MT-ATP6,MT-ND3,MT-ND5 3 
Cellular Movement cell movement of pericytes 
0.00022
2     ITGB1,LGALS1,MIF 3 
Inflammatory Response, Skeletal and 
Muscular Disorders inflammation of limb 
0.00022
2     APOE,LGALS1,MIF 3 
Developmental Disorder, Ophthalmic 
Disease, Organismal Injury and 
Abnormalities congenital anomaly of eye 
0.00022
4     ACTB,APOE,CAV1,CRYAB,FTL,VIM 6 
Hematological System Development 
and Function, Immune Cell 
Trafficking, Inflammatory Response, 
Tissue Development accumulation of macrophages 
0.00023
1     APOE,MIF,SOD1,TIMP1 4 
Hematological Disease, Metabolic 
Disease dyslipidemia 
0.00025




Cellular Assembly and Organization, 
Neurological Disease, Organismal 
Development, Tissue Development formation of amyloid fibrils 
0.00026
7     APOE,CRYAB,SOD1 3 
Neurological Disease dyskinesia 
0.00026
7     
ACTB,APOE,ATP1B1,CAV1,COX7A2,CRYAB,
CYCS,GAPDH,RPSA,TXN,YWHAZ 11 
Nervous System Development and 
Function morphology of nerves 
0.00027
3     APOE,ITGB1,LGALS1,MIF,SOD1 5 
Metabolic Disease disorder of lipid metabolism 
0.00027
4     APOE,CAV1,HSD11B1,IDH1,PTGS1,SOD1 6 
Cancer, Endocrine System Disorders, 
Organismal Injury and Abnormalities, 
Reproductive System Disease ovarian cancer 
0.00027




Vitamin and Mineral Metabolism quantity of vitamin 
0.00027
8     ALDH1A1,APOE,FTH1,SOD1 4 
Connective Tissue Disorders, 
Organismal Injury and Abnormalities, 
Skeletal and Muscular Disorders, 
Tissue Morphology 
abnormal morphology of 
superficial fascia 
0.00027
9     BGN,DCN 2 
Metabolic Disease, Neurological 
Disease, Organismal Injury and 
Abnormalities amyloid load of hippocampus 
0.00027
9     APOE,VIM 2 
Cell Cycle 
interphase of antigen presenting 
cells 
0.00027
9     DCN,ITGB1 2 
Cancer, Developmental Disorder, 
Embryonic Development, Organismal 
Injury and Abnormalities invasion of mesenchyme 
0.00027
9     ALDH1A1,MIF 2 
Neurological Disease, Organismal 
Injury and Abnormalities reactive astrogliosis 
0.00027
9     CTSB,SOD1 2 
Infectious Diseases, Organismal Injury 
and Abnormalities septic shock 0.00028     ALB,ATP1B1,CAV1,MIF,PTGS1,SERPINC1 6 
Cancer, Organismal Injury and 
Abnormalities, Respiratory Disease advanced lung cancer 
0.00029
3     CTSB,FTL,ITGB1,LGALS1,PTGS1,YWHAE 6 
Nucleic Acid Metabolism, Small 
Molecule Biochemistry 
metabolism of nucleoside 
triphosphate 
0.00030
7     ATP1B1,CAV1,CYCS,MT-ATP6,SOD1 5 
Cellular Movement, Hematological 
Disease, Immunological Disease, 
Inflammatory Disease, Inflammatory 
Response, Organismal Injury and 
Abnormalities, Respiratory Disease allergic pulmonary eosinophilia 
0.00031
7     ACTB,ALB,GAPDH 3 
Cancer, Cell Death and Survival, 
Organismal Injury and Abnormalities, 
Tumor Morphology 
apoptosis of chronic lymphocytic 
leukemia cells 
0.00031
7     ALB,MIF,TXN 3 
Cell-To-Cell Signaling and 
Interaction, Cellular Assembly and 
Organization, Cellular Compromise disruption of cell-cell contacts 
0.00031
7     ITGB1,MYLK,SOD1 3 
Cellular Assembly and Organization, 
Cellular Compromise disruption of cytoskeleton 
0.00031
7     CAST,CAV1,ITGB1 3 
Psychological Disorders depressive disorder 
0.00032
2     ALB,APOE,ATP1A1,CRYAB,PF4,POMC,VIM 7 
Drug Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry concentration of glutathione 
0.00033
1     ALDH1A1,FTH1,SOD1,TXN 4 
Skeletal and Muscular System 
Development and Function contraction of smooth muscle 
0.00033





Cell Death and Survival cell death of ganglion cells 
0.00034
4     CYCS,PRKACA,SOD1 3 
Cell Morphology 
abnormal morphology of plasma 
membrane 
0.00034
5     APOE,CAV1,LGALS1,STX1B 4 
Neurological Disease, Organismal 
Injury and Abnormalities astrocytosis 0.00036     APOE,CAV1,CTSB,SOD1 4 
Drug Metabolism, Endocrine System 
Development and Function, Lipid 
Metabolism, Small Molecule 
Biochemistry, Vitamin and Mineral 
Metabolism synthesis of progesterone 0.00036     IGFBP4,POMC,VIM,YWHAG 4 
Hematological Disease hypercoagulation 
0.00037
1     PTGS1,SERPINC1 2 
Cell Cycle interphase of phagocytes 
0.00037
1     DCN,ITGB1 2 
Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry quantity of ganglioside GM2 
0.00037
1     APOE,CTSD 2 
Cell Death and Survival cell death of astrocytes 
0.00037
2     ALB,CRYAB,SOD1 3 
Cardiovascular Disease damage of blood vessel 
0.00037
2     APOE,BGN,POMC 3 
Cellular Development, Connective 
Tissue Development and Function, 
Tissue Development differentiation of stromal cells 
0.00037
2     HSD11B1,ITGB1,SOD1 3 
Lipid Metabolism, Small Molecule 
Biochemistry esterification of cholesterol 
0.00037
2     APOE,CAV1,HSD11B1 3 
Cardiovascular Disease, Neurological 
Disease, Organismal Injury and 
Abnormalities cerebral ischemia 
0.00039
1     ALB,PTGS1,PYGL,SERPINC1 4 
Cell Death and Survival, Organismal 
Injury and Abnormalities, Renal and 
Urological Disease apoptosis of tubular cells 
0.00040
2     ALB,ATP1A1,DCN 3 
Cancer, Cellular Development, 
Cellular Growth and Proliferation, 
Organismal Injury and Abnormalities, 
Tumor Morphology colony formation of cancer cells 
0.00040
2     CAV1,CTSB,DCN 3 
Inflammatory Response, Organismal 
Functions fever 
0.00040
2     MIF,POMC,PTGS1 3 
Organ Development, Renal and 
Urological System Development and 
Function function of kidney 
0.00040
8     ITGB1,MIF,PTGS1,SERPINC1 4 
Organismal Development 
abnormal morphology of body 




Reproductive System Development 
and Function 
morphology of reproductive 
system 
0.00042
3     
ALB,APOE,ASPM,CAV1,CNN1,HSD11B1,ITG
B1,POMC,PTGS1,SOD1,TIMP1 11 
Skeletal and Muscular System 
Development and Function function of smooth muscle 
0.00042











%User must update folder location and make sure all images are numbered 
PicLoc ='C:\Users\Alberto\OneDrive\Documents\Lab Stuff\Hydrogel and OCT 




NumIm=3; %User input for specific # of images in the folder 
for v=1:NumIm 
PicName=num2str(v); 






















aO = inc; %tracing for background sample and vessel core sizes 





maxdist=round((Squarelimit/2)/inc);    











level = graythresh(I5); 
level=(level-0.25*level); %Usuallt 0.15  
bw = im2bw(I5,level); 
% bw = im2bw(I5); 





filled = imfill(bw, 'holes'); 





holes = filled & ~bw; 
bigholes = bwareaopen(holes, 40); %Usualy 50 
smallholes = holes & ~bigholes; 




    c1=xO(v)+(-(sb2/2)+i); 
    for j=1:(sb2) 
        r1=yO(v)+(-(sb2/2)+j); 
         
        bw(r1,c1)=1; 
         











     
    for k=1:th 
        b=a+(-(round(th/2))+k); 
         
    l=length((xO(v)-b):(xO(v)+b)); 
    cxO1=repmat((xO(v)-b),l,1); %define x position of left line 
    cxO2=repmat((xO(v)+b),l,1); %define x position of right line 
    ryO1=repmat((yO(v)-b),l,1); %define y position of top line 




    c=[(xO(v)-b):(xO(v)+b) cxO1' (xO(v)-b):(xO(v)+b) cxO2']; %all x 
positions of square 
    r=[ryO1' (yO(v)-b):(yO(v)+b) ryO2' (yO(v)-b):(yO(v)+b)]; %all y 
positions of square 
     
%         for j=1:length(c) 
%              Squares(c(j),r(j))=1; 
%         end 
         
    pixels = impixel(bw,c,r); %pixel values of all pixels along the 
square 
    S=sum(pixels); 
    branchdensity(k,i)=(S(1)/(l*4)); 
     
    for g=1:length(pixels(:,1))-1 
        Intersection(g,k)= abs(pixels((g+1),1) - pixels((g),1)); 
%Determine if there is an intersection by seeing if pixel changes from 
a 0 to 1 or 1 to 0 
    end 
     
    %Eliminating noise (Branch must be 2 pixels in width) 
    for g=1:length(pixels(:,1))-2 
        CurrentBranchLength(g)=0; 
        if Intersection(g,k)+Intersection(g+1,k)>1 
            Intersection(g,k)=0; 
        elseif Intersection(g,k)+Intersection(g+1,k)==1 
            CurrentBranchLength(g)=sqrt((abs(xO(v)-c(g)))^2+(abs(yO(v)-
r(g)))^2); 
        end 
    end 
     
    MaxBranchLength(i)=max(CurrentBranchLength)/pix2mm; 
  
     
    
    Intersection((length(pixels(:,1))+1),k) = sum(Intersection(:,k)); 
    MaxInt(i,k)= max(Intersection(:,k)); 
    end 
    
    branchdensity((th+1),i) = mean(branchdensity(:,i)); 
    NumInter(i)=mean(MaxInt(i,:))/2; 
    a=a+inc; 




BranchLengthindex = find(branchdensity((th+1),:)<0.015,1); 
BranchLengthindex2 = find(branchdensity((th+1),:)<(5/l),1); 
  
TF = isempty(BranchLengthindex); 
  
if TF==1 
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